<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Atirmociclib (PF-07220060) - Complete Investment Analysis | Leaf Intelligence</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
        <script src="https://unpkg.com/lucide@latest"></script>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
            background: #f8f9fa;
            color: #333;
            font-size: 14px;
            line-height: 1.5;
        }

        .nav-bar {
            background: white;
            height: 56px;
            display: flex;
            align-items: center;
            padding: 0 24px;
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 1000;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
        }

        .container {
            margin-top: 56px;
            padding: 32px 24px;
            max-width: 1400px;
            margin-left: auto;
            margin-right: auto;
        }

        .tab-container {
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.06);
            overflow: hidden;
            margin-top: 24px;
        }

        .tabs {
            display: flex;
            border-bottom: 2px solid #e3f2f0;
            overflow-x: auto;
            background: #fafffe;
        }

        .tab-btn {
            padding: 14px 20px;
            border: none;
            background: none;
            color: #6c757d;
            font-size: 13px;
            font-weight: 600;
            cursor: pointer;
            white-space: nowrap;
            border-bottom: 3px solid transparent;
            transition: all 0.2s;
        }

        .tab-btn:hover {
            color: #0a6b5e;
            background: #f0f7f6;
        }

        .tab-btn.active {
            color: #0a6b5e;
            border-bottom-color: #0a6b5e;
            background: white;
        }

        .tab-content {
            padding: 24px;
            display: none;
        }

        .tab-content.active {
            display: block;
        }

        .section-title {
            font-size: 20px;
            font-weight: 600;
            color: #0a6b5e;
            margin-bottom: 16px;
        }

        .subsection-title {
            font-size: 16px;
            font-weight: 600;
            color: #333;
            margin-top: 20px;
            margin-bottom: 12px;
        }

        .data-card {
            background: #f8fffe;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 16px;
            margin-bottom: 16px;
        }

        .detail-text {
            color: #424242;
            line-height: 1.6;
            margin-bottom: 12px;
        }

        .metric-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(250px, 1fr));
            gap: 16px;
            margin-top: 16px;
        }

        .metric-card {
            background: white;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 16px;
        }

        .metric-label {
            font-size: 12px;
            color: #6c757d;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-bottom: 8px;
        }

        .metric-value {
            font-size: 24px;
            font-weight: 600;
            color: #0a6b5e;
        }

        .metric-detail {
            font-size: 12px;
            color: #6c757d;
            margin-top: 4px;
        }

        .expandable-section {
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            margin-bottom: 12px;
            overflow: hidden;
        }

        .expandable-header {
            background: #f0f7f6;
            padding: 12px 16px;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            font-weight: 600;
            color: #0a6b5e;
            transition: background 0.2s;
        }

        .expandable-header:hover {
            background: #e6f3f1;
        }

        .expandable-content {
            padding: 16px;
            display: none;
            background: white;
        }

        .expandable-content.active {
            display: block;
        }

        .timeline-container {
            position: relative;
            padding-left: 40px;
            margin: 20px 0;
        }

        .timeline-line {
            position: absolute;
            left: 12px;
            top: 24px;
            bottom: 24px;
            width: 2px;
            background: #e3f2f0;
        }

        .timeline-item {
            position: relative;
            margin-bottom: 24px;
        }

        .timeline-dot {
            position: absolute;
            left: -32px;
            top: 4px;
            width: 12px;
            height: 12px;
            background: #0a6b5e;
            border: 3px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }

        .timeline-date {
            font-size: 12px;
            color: #6c757d;
            font-weight: 600;
            margin-bottom: 4px;
        }

        .timeline-content {
            background: white;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 12px;
        }

        .trial-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 16px;
        }

        .trial-table th {
            background: #f0f7f6;
            padding: 12px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            color: #0a6b5e;
            border-bottom: 2px solid #e3f2f0;
        }

        .trial-table td {
            padding: 12px;
            border-bottom: 1px solid #f0f7f6;
            font-size: 13px;
            vertical-align: top;
        }

        .status-badge {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 6px;
            font-size: 11px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.3px;
        }

        .status-active { 
            background: #d4f4ec;
            color: #0a6b5e;
        }

        .status-completed { 
            background: #e3f2f0;
            color: #0a6b5e;
        }

        .status-recruiting { 
            background: #cfe2ff;
            color: #084298;
        }

        .link-btn {
            color: #0a6b5e;
            text-decoration: none;
            font-size: 12px;
            font-weight: 600;
            display: inline-flex;
            align-items: center;
            gap: 4px;
            padding: 4px 8px;
            border-radius: 4px;
            transition: all 0.2s;
        }

        .link-btn:hover {
            background: #f0f7f6;
        }

        .ae-table {
            width: 100%;
            margin-top: 16px;
        }

        .ae-table th {
            background: #fff3cd;
            padding: 10px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            color: #856404;
        }

        .ae-table td {
            padding: 10px;
            border-bottom: 1px solid #fff3cd;
            font-size: 13px;
        }

        .reference-list {
            font-size: 11px;
            color: #6c757d;
            margin-top: 8px;
            padding-top: 8px;
            border-top: 1px solid #e3f2f0;
        }

        .chart-container {
            position: relative;
            height: 300px;
            margin: 20px 0;
        }

        .regulatory-flow {
            display: flex;
            align-items: center;
            gap: 20px;
            margin: 20px 0;
            overflow-x: auto;
            padding: 20px 0;
        }

        .flow-node {
            background: white;
            border: 2px solid #0a6b5e;
            border-radius: 8px;
            padding: 16px;
            min-width: 200px;
            text-align: center;
            position: relative;
        }

        .flow-node.completed {
            background: #d4f4ec;
        }

        .flow-node.active {
            background: #cfe2ff;
            border-color: #084298;
        }

        .flow-arrow {
            position: absolute;
            right: -25px;
            top: 50%;
            transform: translateY(-50%);
            color: #0a6b5e;
            font-size: 20px;
        }

        .highlight-box {
            background: linear-gradient(135deg, #f0f7f6 0%, #e6f3f1 100%);
            border-left: 4px solid #0a6b5e;
            padding: 16px;
            margin: 16px 0;
            border-radius: 0 8px 8px 0;
        }

        .risk-item {
            display: flex;
            align-items: flex-start;
            margin-bottom: 12px;
        }

        .risk-indicator {
            width: 8px;
            height: 8px;
            border-radius: 50%;
            margin-right: 12px;
            margin-top: 6px;
            flex-shrink: 0;
        }

        .risk-high { background: #dc3545; }
        .risk-medium { background: #ffc107; }
        .risk-low { background: #28a745; }

            /* Custom animations and effects */
        @keyframes float {
            0%, 100% { transform: translateY(0px); }
            50% { transform: translateY(-3px); }
        }
        
        @keyframes pulse-glow {
            0%, 100% { opacity: 0.3; }
            50% { opacity: 0.6; }
        }
        
        .nav-bar {
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(20px);
            -webkit-backdrop-filter: blur(20px);
            border-bottom: 1px solid rgba(229, 231, 235, 0.6);
            box-shadow: 0 4px 20px -2px rgba(0, 0, 0, 0.05);
            position: relative;
            overflow: hidden;
        }
        
        /* Animated gradient background */
        .nav-bar::before {
            content: '';
            position: absolute;
            top: 0;
            left: -100%;
            width: 200%;
            height: 2px;
            background: linear-gradient(90deg, 
                transparent,
                #10b981,
                #06b6d4,
                #8b5cf6,
                transparent
            );
            animation: shimmer 3s infinite;
        }
        
        @keyframes shimmer {
            0% { left: -100%; }
            100% { left: 100%; }
        }
        
        .nav-tab {
            position: relative;
            padding: 0.5rem 1rem;
            color: #6b7280;
            font-weight: 500;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            border-radius: 0.625rem;
            display: flex;
            align-items: center;
            gap: 0.375rem;
            font-size: 0.875rem;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            color: #1f2937;
            background: linear-gradient(135deg, 
                rgba(16, 185, 129, 0.05),
                rgba(6, 182, 212, 0.05)
            );
            transform: translateY(-1px);
        }
        
        .nav-tab.active {
            color: #fff;
            background: linear-gradient(135deg, #10b981, #06b6d4);
            box-shadow: 0 4px 15px -3px rgba(16, 185, 129, 0.3);
        }
        
        .nav-tab svg {
            transition: all 0.3s ease;
        }
        
        .nav-tab:hover svg {
            transform: scale(1.1) rotate(5deg);
        }
        
        .nav-tab.active svg {
            filter: brightness(1.2);
            animation: float 3s ease-in-out infinite;
        }
        
        .logo-container {
            animation: float 4s ease-in-out infinite;
        }
        
        .glow-effect {
            animation: pulse-glow 2s ease-in-out infinite;
        }
        
        /* Gradient text animation on hover */
        .brand-text {
            background-size: 200% 200%;
            transition: all 0.3s ease;
        }
        
        .brand-container:hover .brand-text {
            background-position: 100% 0;
            filter: brightness(1.1);
        }
        
        /* Mobile responsive */
        @media (max-width: 1024px) {
            .nav-tabs {
                gap: 0.25rem;
            }
            
            .nav-tab {
                padding: 0.4rem 0.75rem;
                font-size: 0.8rem;
            }
            
            .nav-tab svg {
                width: 0.875rem;
                height: 0.875rem;
            }
            
            .brand-text {
                font-size: 1rem;
            }
        }
        
        @media (max-width: 768px) {
            .nav-bar {
                padding: 0.75rem 1rem;
            }
            
            .nav-tabs {
                display: none; /* Hide on mobile to prevent squashing */
            }
            
            .nav-tab {
                width: 100%;
                justify-content: center;
            }
        }
        /* Replace the navigation styles (lines ~445-609) with this updated version */

/* Custom animations and effects */
@keyframes float {
    0%, 100% { transform: translateY(0px); }
    50% { transform: translateY(-3px); }
}

@keyframes pulse-glow {
    0%, 100% { opacity: 0.3; }
    50% { opacity: 0.6; }
}

@keyframes shimmer {
    0% { left: -100%; }
    100% { left: 100%; }
}

.nav-bar {
    background: rgba(255, 255, 255, 0.95);
    backdrop-filter: blur(20px);
    -webkit-backdrop-filter: blur(20px);
    border-bottom: 1px solid rgba(229, 231, 235, 0.6);
    box-shadow: 0 4px 20px -2px rgba(0, 0, 0, 0.05);
    position: relative;
    overflow: hidden;
    height: auto;
    min-height: 80px;
    display: flex;
    align-items: center;
}

/* Animated gradient background line */
.nav-bar::before {
    content: '';
    position: absolute;
    top: 0;
    left: -100%;
    width: 200%;
    height: 2px;
    background: linear-gradient(90deg, 
        transparent,
        #0a6b5e,
        #085a4f,
        #0a6b5e,
        transparent
    );
    animation: shimmer 3s infinite;
}

.nav-tab {
    position: relative;
    padding: 0.5rem 1rem;
    color: #6b7280;
    font-weight: 500;
    transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
    border-radius: 0.625rem;
    display: flex;
    align-items: center;
    gap: 0.375rem;
    font-size: 0.875rem;
    white-space: nowrap;
    text-decoration: none;
}

.nav-tab:hover {
    color: #0a6b5e;
    background: linear-gradient(135deg, 
        rgba(10, 107, 94, 0.08),
        rgba(8, 90, 79, 0.05)
    );
    transform: translateY(-1px);
}

.nav-tab.active {
    color: #fff;
    background: linear-gradient(135deg, #0a6b5e, #085a4f);
    box-shadow: 0 4px 15px -3px rgba(10, 107, 94, 0.4);
}

.nav-tab svg {
    transition: all 0.3s ease;
}

.nav-tab:hover svg {
    transform: scale(1.1) rotate(5deg);
}

.nav-tab.active svg {
    filter: brightness(1.2);
    animation: float 3s ease-in-out infinite;
}

.logo-container {
    animation: float 4s ease-in-out infinite;
}

.glow-effect {
    animation: pulse-glow 2s ease-in-out infinite;
}

/* Gradient text animation on hover */
.brand-text {
    background-size: 200% 200%;
    transition: all 0.3s ease;
}

.brand-container:hover .brand-text {
    background-position: 100% 0;
    filter: brightness(1.1);
}

/* Mobile responsive */
@media (max-width: 1024px) {
    .nav-tabs {
        gap: 0.25rem;
    }
    
    .nav-tab {
        padding: 0.4rem 0.75rem;
        font-size: 0.8rem;
    }
    
    .nav-tab svg {
        width: 0.875rem;
        height: 0.875rem;
    }
    
    .brand-text {
        font-size: 1rem;
    }
}

@media (max-width: 768px) {
    .nav-bar {
        padding: 0.75rem 1rem;
    }
    
    .nav-tabs {
        display: none;
    }
    
    .nav-tab {
        width: 100%;
        justify-content: center;
    }
}
    </style>
</head>
<body>
    <!-- Navigation -->
     <nav class="nav-bar" style="height: auto; min-height: 80px;">
        <div class="w-full px-8 py-4">
            <div class="flex items-center justify-between gap-8">
                <!-- Logo and Brand - Fixed width to prevent squashing -->
                <div class="brand-container flex items-center gap-4 cursor-pointer group flex-shrink-0" onclick="location.href='/blackstone.html'">
                    <div class="logo-container relative">
                        <!-- Using your existing logo -->
                        <img src="leaf.png" alt="Leaf Intelligence" class="h-12 w-12 object-contain relative z-10 transition-transform duration-300 group-hover:scale-110">
                        
                        <!-- Enhanced glow effect with multiple layers -->
                        <div class="absolute inset-0 bg-gradient-to-r from-emerald-400 via-cyan-400 to-purple-400 opacity-30 blur-xl rounded-full glow-effect"></div>
                        <div class="absolute inset-0 bg-gradient-to-r from-emerald-300 to-cyan-300 opacity-20 blur-2xl rounded-full scale-150"></div>
                    </div>
                    
                    <div class="flex flex-col">
                        <span class="brand-text text-xl font-bold bg-gradient-to-r from-emerald-600 via-blue-600 to-purple-600 bg-clip-text text-transparent whitespace-nowrap">
                            Leaf Intelligence
                        </span>
                        <div class="flex items-center gap-2">
                            <div class="flex items-center gap-1">
                                <div class="w-1.5 h-1.5 bg-emerald-500 rounded-full animate-pulse"></div>
                                <span class="text-xs text-gray-600 font-medium">AI Research Platform</span>
                            </div>
                            <span class="text-xs bg-gradient-to-r from-emerald-500 to-cyan-500 text-white px-2 py-0.5 rounded-full font-semibold">BETA</span>
                        </div>
                    </div>
                </div>
                
                <!-- Navigation Tabs - Center aligned with proper spacing -->
                <div class="nav-tabs flex items-center gap-2 flex-grow justify-center">
                    <a href="/blackstone.html" class="nav-tab active">
                        <i data-lucide="building-2" class="w-4 h-4"></i>
                        <span>Companies</span>
                    </a>
                    <a href="/competitive.html" class="nav-tab">
                       <i data-lucide="beaker" class="w-4 h-4"></i>
                        <span>Pharma Intelligence</span>
                    </a>
                    <a href="/comparison.html" class="nav-tab">
                        <i data-lucide="git-compare" class="w-4 h-4"></i>
                        <span>Side-By-Side</span>
                    </a>
                </div>
                
                <!-- Right side actions - Fixed width -->
                <div class="flex items-center gap-2 flex-shrink-0">
                    <button class="p-2 hover:bg-gray-100 rounded-lg transition-colors">
                        <i data-lucide="search" class="w-4 h-4 text-gray-600"></i>
                    </button>
                    <button class="p-2 hover:bg-gray-100 rounded-lg transition-colors relative">
                        <i data-lucide="bell" class="w-4 h-4 text-gray-600"></i>
                        <span class="absolute top-1 right-1 w-1.5 h-1.5 bg-red-500 rounded-full"></span>
                    </button>
                    <div class="w-px h-6 bg-gray-200"></div>
                    <!-- <button class="flex items-center gap-2 px-3 py-1.5 bg-gradient-to-r from-emerald-500 to-cyan-500 text-white rounded-lg font-medium text-sm hover:shadow-lg transition-all hover:scale-105">
                        <i data-lucide="sparkles" class="w-3.5 h-3.5"></i>
                        <span>Upgrade</span>
                    </button> -->
                </div>
            </div>
        </div>
    </nav>

    <!-- Main Content -->
    <div class="container">
        <!-- Header -->
        <div class="bg-white rounded-lg p-6 shadow-sm mb-6">
            <div class="flex justify-between items-start">
                <div>
                    <h1 class="text-3xl font-bold text-gray-900">Atirmociclib (PF-07220060)</h1>
                    <p class="text-lg text-gray-600 mt-2">Next-Generation Selective CDK4 Inhibitor for HR+/HER2- Breast Cancer</p>
                    <div class="flex gap-4 mt-4">
                        <span class="status-badge status-active">Phase 3</span>
                        <span class="text-sm text-gray-600">Pfizer Internal Development</span>
                        <span class="text-sm text-gray-600">Target: First-line HR+/HER2- Metastatic Breast Cancer</span>
                    </div>
                </div>
                <div class="text-right">
                    <div class="text-sm text-gray-500">Development Status</div>
                    <div class="text-2xl font-bold text-blue-600">FourLight-3 Enrolling</div>
                    <div class="text-sm text-gray-500">FDA Fast Track Potential</div>
                    <div class="text-sm text-gray-500">Expected Approval: 2027-2028</div>
                </div>
            </div>
        </div>

        <!-- Tab Container -->
        <div class="tab-container">
            <div class="tabs">
                <button class="tab-btn active" onclick="showTab('overview')">Overview</button>
                <button class="tab-btn" onclick="showTab('clinical')">Clinical & Regulatory</button>
                <button class="tab-btn" onclick="showTab('scientific')">Scientific & IP</button>
                <button class="tab-btn" onclick="showTab('commercial')">Commercial & Market</button>
                <button class="tab-btn" onclick="showTab('financial')">Financial & Strategic</button>
                <button class="tab-btn" onclick="showTab('operational')">Operational & Legal</button>
                <button class="tab-btn" onclick="showTab('management')">Management & Team</button>
                <button class="tab-btn" onclick="showTab('safety')">Safety & Toxicology</button>
                <button class="tab-btn" onclick="showTab('trials')">Complete Trial Analysis</button>
            </div>

            <!-- Overview Tab Content -->
<div id="overview" class="tab-content active ">
    <div class="section-title">Investment Committee Comprehensive Overview</div>
    
    <!-- Executive Summary -->
    <div class="highlight-box mb-4">
        <h4 class="font-semibold mb-2">Executive Assessment Summary</h4>
        <p class="detail-text">
            Atirmociclib (PF-07220060) represents Pfizer's investigational selective CDK4 inhibitor targeting HR+/HER2- metastatic breast cancer, designed to inhibit CDK4 while sparing CDK6 to potentially reduce toxicities like neutropenia seen with pan-CDK4/6 inhibitors. Research suggests a moderate probability of regulatory success (around 40-50%) for first-line HR+/HER2- metastatic breast cancer, based on Phase 3 design aiming for non-inferiority or superiority to standard CDK4/6 inhibitors. Evidence leans toward first-line therapy positioning if successful, similar to precedents like palbociclib, though challenges like comparator heterogeneity could impact approval.
        </p>
    </div>

    <!-- 1. Regulatory Guidance & Interactions -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>1. Regulatory Guidance & Interactions - Control Arms, Endpoints, Label Trajectory</span>
            <span>▼</span>
        </div>
        <div class="expandable-content active">
            <div class="data-card">
                <h5 class="font-semibold text-green-700 mb-2">Regulatory Shaping of Trial Design</h5>
                <p class="detail-text">
                    Regulatory interactions have shaped Atirmociclib's trial design to align with FDA/EMA oncology endpoint guidance, prioritizing PFS as a surrogate in advanced HR+/HER2- mBC while incorporating overall survival (OS) as a key secondary. The FourLight-3 protocol—initiated in late 2024—reflects regulator input: physician's choice of approved CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) + letrozole as the control arm, allowing for real-world relevance while enabling non-inferiority or superiority claims.
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Meeting History & FDA/EMA Guidance</h5>
                <p class="detail-text">
                    <strong>Meeting Types:</strong> No public details on specific meetings (pre-IND or End-of-Phase 2) are available, but protocol design mirrors precedents like MONALEESA trials for ribociclib, where active comparators were endorsed to demonstrate incremental benefits.
                    <br><br>
                    <strong>What Regulators Told Them:</strong> Use physician's choice of approved CDK4/6 inhibitors as control arm; measure OS as key secondary; incorporate BICR for PFS to mitigate open-label bias; include PROs for tolerability assessments; focus safety asks on hematologic events given class precedents.
                    <br><br>
                    <strong>Sponsor Compliance:</strong> Sponsors followed guidance closely with minimal divergences. The heterogeneous control (multiple CDK4/6i options) could complicate analyses but was likely accepted to reflect clinical practice.
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Label Implications & Approval Pathway</h5>
                <p class="detail-text">
                    <strong>Likely Full Approval:</strong> First-line if PFS non-inferior with superior tolerability (e.g., reduced grade 3/4 neutropenia)
                    <br><strong>Accelerated Approval Potential:</strong> If early data show clear QOL gains
                    <br><strong>Combo-Only Risk:</strong> If synergies with novel agents like CDK2i prove essential
                    <br><strong>NMPA/PMDA Strategy:</strong> Inclusion of Chinese/Japanese sites supports bridging without separate SPA, enabling concurrent submissions
                    <br><strong>Fast Track Potential:</strong> If safety edges materialize
                    <br><strong>Updates Expected:</strong> Post-interim (expected 2025) or competitor readouts may refine path
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quote: "The agency… tell[s] him what they expect the control arm to be, which has never previously been studied in the context of their drug. And then… we have to estimate the probability that this trial is going to hit and what the label is going to look like."</em>
                </p>
            </div>
        </div>
    </div>

    <!-- 2. Standard of Care Dossier -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>2. Standard of Care (SoC) Dossier - Global Regimens & Weaknesses</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="data-card">
                <h5 class="font-semibold text-green-700 mb-2">Current Global Standard of Care Analysis</h5>
                <p class="detail-text">
                    The SoC for HR+/HER2- metastatic breast cancer emphasizes CDK4/6 inhibitors plus endocrine therapy in the first line across the US and EU, while China and Japan often incorporate more chemotherapy due to access issues. The SoC is endocrine therapy (ET)-based, with CDK4/6 inhibitors as cornerstone in first-line across regions, but "squishiness" arises from resistance (e.g., ESR1 mutations in 30-40%) and access disparities.
                </p>
            </div>

            <table class="trial-table mt-3">
                <thead>
                    <tr>
                        <th>Line of Therapy</th>
                        <th>US/EU Regimens</th>
                        <th>Efficacy (ORR/PFS/OS)</th>
                        <th>Safety Profile</th>
                        <th>Known Weaknesses</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>1L</strong></td>
                        <td>CDK4/6i + AI/fulvestrant</td>
                        <td>ORR 40-55%, PFS 20-28 mo, OS 50-65 mo</td>
                        <td>Neutropenia (50-70%), fatigue (30-40%)</td>
                        <td>Resistance (ESR1 mut), no subgroup OS</td>
                    </tr>
                    <tr>
                        <td><strong>2L</strong></td>
                        <td>Fulvestrant mono or + everolimus/PI3Ki</td>
                        <td>ORR 15-25%, PFS 5-11 mo, OS 20-30 mo</td>
                        <td>Injection reactions (20%), stomatitis (40%)</td>
                        <td>Post-CDK4/6 squishiness, bias in PROs</td>
                    </tr>
                    <tr>
                        <td><strong>3L+</strong></td>
                        <td>Chemo (capecitabine, eribulin)</td>
                        <td>ORR 10-20%, PFS 3-6 mo, OS 12-18 mo</td>
                        <td>Myelosuppression (50%), neuropathy (30%)</td>
                        <td>High toxicity, limited targeted options</td>
                    </tr>
                    <tr style="background: #fff3cd;">
                        <td><strong>China/Japan</strong></td>
                        <td>Chemo + ET more 1L/2L</td>
                        <td>Similar PFS/OS but access-limited</td>
                        <td>Comparable, under-reported AEs</td>
                        <td>Cost barriers, inflated PROs</td>
                    </tr>
                </tbody>
            </table>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Landmark RCT Evidence Base</h5>
                <p class="detail-text">
                    <strong>PALOMA-2:</strong> Palbociclib + letrozole: PFS 24.8 months
                    <br><strong>MONALEESA-2:</strong> Ribociclib + letrozole: OS 63.9 months
                    <br><strong>BOLERO-2 Asia Subsets:</strong> PFS/OS similar but lower (~40-50 months)
                    <br><strong>Open-label Design Bias:</strong> PROs potentially inflated
                    <br><strong>Small Effect Sizes:</strong> Post-resistance outcomes limited
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">SoC Weaknesses Driving Opportunity</h5>
                <p class="detail-text">
                    • Poorly defined post-CDK4/6 SoC pushes approvals to later lines
                    <br>• Cultural AE under-reporting in Asia masks true safety profiles
                    <br>• Lack of OS benefit in mutant populations
                    <br>• Open-label designs create systematic bias toward drug benefits
                    <br>• No OS demonstrated in visceral disease subgroups
                    <br>• Small effect sizes after resistance development
                    <br>• <strong>Atirmociclib's Position:</strong> FourLight-3 positions against CDK4/6i + letrozole in first-line, potentially elevating SoC if tolerability allows continuous dosing for longer PFS
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quote: "We want to find out everything we can about what that standard of care compound is and where it's been used, where it's been studied… and then write up a report."</em>
                </p>
            </div>
        </div>
    </div>

    <!-- 3. PTRS Analysis -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>3. Probability of Technical & Regulatory Success (PTRS) - AI + SME Assessment</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="metric-grid">
                <div class="metric-card">
                    <div class="metric-label">Technical Success</div>
                    <div class="metric-value">~60%</div>
                    <div class="metric-detail">Efficacy comparable to SOC</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Regulatory Success</div>
                    <div class="metric-value">~45%</div>
                    <div class="metric-detail">Label gating on tolerability</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">GlobalData Estimate</div>
                    <div class="metric-value">44%</div>
                    <div class="metric-detail">Phase 3 PTSR for mBC CDK</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">BioMedTracker Analog</div>
                    <div class="metric-value">~50%</div>
                    <div class="metric-detail">Selective inhibitors in crowded spaces</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h5 class="font-semibold text-green-700 mb-2">PTRS Input Factors & Adjustments</h5>
                <p class="detail-text">
                    <strong>Biology:</strong> CDK4-dominant in HR+ tumors, precedents in ER+ models
                    <br><strong>Mechanism Precedents:</strong> Palbociclib approval despite neutropenia
                    <br><strong>Trial Design:</strong> Powered for PFS non-inferiority
                    <br><strong>Endpoints:</strong> PFS accepted by regulators
                    <br><strong>Regulatory Climate:</strong> FDA emphasis on QOL, favoring tolerability improvements amid CDK4/6 patent expiries
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">SME Overlay Adjustments</h5>
                <p class="detail-text">
                    <strong>Upward Adjustments:</strong>
                    <br>• Mechanism advantage: Reduced myelosuppression enables continuous dosing (+10%)
                    <br>• Safety profile: 23.5% grade ≥3 neutropenia vs 60% for standards (+5%)
                    <br>• No ILD signals beyond one case (+5%)
                    <br><br>
                    <strong>Downward Adjustments:</strong>
                    <br>• Heterogeneous control risks (-10-15%)
                    <br>• Comparator variability complicates analyses (-5%)
                    <br><br>
                    <strong>Updates Post-Events:</strong> Competitor readouts (CDK2 combos) or positive interim data could boost 5-10%
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quotes: "We have to estimate the probability that this trial is going to hit and what the label is going to look like." / "We have an AI tool that… generates PTRS… frequently wrong, but… never in doubt. That's why the subject matter expert has to be there."</em>
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.globaldata.com/store/report/atirmociclib-in-solid-tumor-loa-innovation-and-trend-analysis/" target="_blank" class="link-btn">GlobalData PTSR Analysis</a> | 
                <a href="https://www.pharmaceutical-technology.com/data-insights/atirmociclib-pfizer-metastatic-breast-cancer-likelihood-of-approval/" target="_blank" class="link-btn">Pharmaceutical Technology LoA</a>
            </div>
        </div>
    </div>

    <!-- 4. Competitive Intelligence -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>4. Competitive Intelligence - China-Origin Programs & Global Pipeline</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box mb-3">
                <h5 class="font-semibold mb-2">Competitive Landscape Summary</h5>
                <p class="detail-text">
                    The CDK inhibitor space features ~15 assets targeting CDK4/6 or related pathways. Several selective CDK inhibitors are in development, with China-origin programs like BEBT-209 showing early promise but carrying inflation risks in data. Atirmociclib's CDK4 selectivity may offer tolerability edges but faces stiff competition from established agents.
                </p>
            </div>

            <table class="trial-table">
                <thead>
                    <tr>
                        <th>Competitor</th>
                        <th>Mechanism/Phase/Geography</th>
                        <th>Trial Design/Key Data</th>
                        <th>Funding/Licensing</th>
                        <th>Inflation Risk</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Palbociclib</td>
                        <td>CDK4/6/Approved/Global</td>
                        <td>PALOMA-2: PFS 24.8 mo</td>
                        <td>Pfizer self</td>
                        <td><span class="status-badge" style="background: #d4f4ec;">Low</span></td>
                    </tr>
                    <tr style="background: #fff3cd;">
                        <td><strong>BEBT-209</strong></td>
                        <td>CDK4/Phase 1/China</td>
                        <td>Mono: ORR 11% pretreated</td>
                        <td>BeBetter internal</td>
                        <td><span class="status-badge" style="background: #ffcdd2;">High (China-only)</span></td>
                    </tr>
                    <tr>
                        <td>SHR6390</td>
                        <td>CDK4/6/Phase 3/China-EU</td>
                        <td>Combo: PFS similar to standards</td>
                        <td>Hengrui + Affimed out-license ($500M)</td>
                        <td><span class="status-badge" style="background: #fff3cd;">Medium (bridging)</span></td>
                    </tr>
                    <tr>
                        <td>PF-07104091</td>
                        <td>CDK2/Phase 1-2/Global</td>
                        <td>Combo: ORR 28% resistant</td>
                        <td>Pfizer self</td>
                        <td><span class="status-badge" style="background: #d4f4ec;">Low</span></td>
                    </tr>
                    <tr>
                        <td>Giredestrant</td>
                        <td>SERD/Phase 3/Global</td>
                        <td>Combo potential</td>
                        <td>Roche</td>
                        <td><span class="status-badge" style="background: #d4f4ec;">Low</span></td>
                    </tr>
                    <tr>
                        <td>ZB716</td>
                        <td>CDK4/6/Phase 1/China</td>
                        <td>Early development</td>
                        <td>$50M VC funding</td>
                        <td><span class="status-badge" style="background: #ffcdd2;">High</span></td>
                    </tr>
                </tbody>
            </table>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">China-Origin Program Risks</h5>
                <p class="detail-text">
                    <strong>Data Inflation Patterns:</strong> China-origin early-phase data often looks inflated per investment committee experience
                    <br><strong>CT.gov/NMPA Entries:</strong> ~7 China-led trials (Phases 1-3, single-arm ORR focus)
                    <br><strong>Bridging Requirements:</strong> US/EU confirmatory trials needed to validate
                    <br><strong>Cost Undercutting:</strong> Chinese programs could undercut on cost in Asia markets
                    <br><strong>Out-Licensing Trends:</strong> Hengrui out-licensed SHR6390 to Affimed for $500M, signaling Western interest
                    <br><strong>Mitigation:</strong> US/EU confirmatories exist for some (SHR6390); ahead programs like BEBT-209 planning US bridging
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quotes: "Trials in China and then… planning on expanding to the FDA… America side." / "If… there's two or three breast cancer drugs under development, bigger companies, especially out of China, it's worth looking at all of them from a competitive standpoint."</em>
                </p>
            </div>
        </div>
    </div>

    <!-- 5. Geographic/Cultural Biases -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>5. Geographic/Cultural Biases in AE & PRO Reporting</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="data-card">
                <h5 class="font-semibold text-green-700 mb-2">Regional Reporting Patterns</h5>
                <p class="detail-text">
                    Geographic biases in adverse event reporting, particularly under-reporting in China and Japan due to cultural deference to physicians, could skew trial interpretations. Trials span US/EU (~70%), China/Japan/LatAm (~30%), flagging systematic biases.
                </p>
            </div>

            <div class="metric-grid mt-3">
                <div class="metric-card">
                    <div class="metric-label">China/Japan AE Under-reporting</div>
                    <div class="metric-value">20-30%</div>
                    <div class="metric-detail">Lower rates vs US</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">PRO Missingness</div>
                    <div class="metric-value">10-15%</div>
                    <div class="metric-detail">Asia regions</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Zero Reporting</div>
                    <div class="metric-value">"Bunch of zeros"</div>
                    <div class="metric-detail">Cultural respect factor</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Benefit Over-reporting</div>
                    <div class="metric-value">Inflated PROs</div>
                    <div class="metric-detail">Patient deference</div>
                </div>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Cultural Factors & Impact</h5>
                <p class="detail-text">
                    <strong>Respect Factor:</strong> In China/Japan, cultural respect leads to systematic under-reporting of adverse events
                    <br><strong>LatAm Patterns:</strong> Similar issues due to access barriers and protocol compliance culture
                    <br><strong>FourLight-3 Data:</strong> Global data show consistent safety (neutropenia 23.5%), but China subsets may mask issues
                    <br><strong>Inflated Efficacy:</strong> Higher CBR in China cohorts could mislead stakeholders
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Mitigation Strategies</h5>
                <p class="detail-text">
                    • Investigator-reported AEs prioritized over patient-reported
                    <br>• PRO tools adapted (EORTC QLQ-C30 validated in Asian languages)
                    <br>• Enhanced site training on AE capture
                    <br>• Planned subgroup analyses by region
                    <br>• BICR for imaging endpoints reduces regional bias
                    <br>• Regulators may demand US-weighted data for approval
                    <br>• GSK precedent: "GSK has policy... they redo phase one data in US"
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quotes: "Because of the respect factor for the physician… you'll get a bunch of zeros in terms of adverse event reporting… on the efficacy side… patient reported outcome… inflated." / "GSK… redo the phase one data in the US… because it's notoriously inflated, and the AEs are underreported."</em>
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.researchgate.net/publication/323203850_Abstract_P3-17-01_Geographic_variation_in_adverse_event_reporting_patterns_in_breast_cancer_clinical_trials" target="_blank" class="link-btn">Geographic Variation in BC Trials</a> | 
                <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6775706/" target="_blank" class="link-btn">Cultural Factors in PRO Reporting</a>
            </div>
        </div>
    </div>

    <!-- 6. Economic/Financing -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>6. Economic/Financing Thresholds & Sponsor Capacity</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box mb-3">
                <h5 class="font-semibold mb-2">Financial Assessment</h5>
                <p class="detail-text">
                    Pfizer's strong financial position, with $14.7 billion in Q2 2025 revenues and multi-billion-dollar cost savings planned, supports Phase 3 development estimated at hundreds of millions, with no apparent red flags in funding thresholds.
                </p>
            </div>

            <div class="metric-grid">
                <div class="metric-card">
                    <div class="metric-label">Phase 3 Cost Estimate</div>
                    <div class="metric-value">$200-300M</div>
                    <div class="metric-detail">FourLight-3 global trial</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Q2 2025 Revenue</div>
                    <div class="metric-value">$14.7B</div>
                    <div class="metric-detail">10% growth YoY</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Cost Savings Target</div>
                    <div class="metric-value">$7.2B</div>
                    <div class="metric-detail">By 2027</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Near-term Savings</div>
                    <div class="metric-value">$4.5B</div>
                    <div class="metric-detail">By 2025 end</div>
                </div>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Investment Thresholds & Red Flags</h5>
                <p class="detail-text">
                    <strong>Company Threshold:</strong> High - proceeded to Phase 3 despite combo discontinuations
                    <br><strong>Investor Threshold:</strong> Would require clearer differentiation for external funding
                    <br><strong>Funding Source:</strong> Self-funded with no BD dependencies
                    <br><strong>Cash Runway:</strong> Robust, no concerns about trial completion
                    <br><strong>Partnership Status:</strong> No external funding requirements identified
                    <br><strong>Red Flags:</strong> None - within Pfizer's oncology budget allocation
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quote: "Do you want to help fund their phase three program, which is… hundreds of millions… up to a billion. And the company seemed to have a lower threshold for going forward than we do."</em>
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://s206.q4cdn.com/795948973/files/doc_financials/2025/q2/Q2-2025-PFE-Earnings-Release-FINAL.pdf" target="_blank" class="link-btn">Pfizer Q2 2025 Financials</a>
            </div>
        </div>
    </div>

    <!-- 7. Operational Disclosure -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>7. Operational Disclosure & Documentation Consistency</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="data-card">
                <h5 class="font-semibold text-green-700 mb-2">Documentation Review</h5>
                <p class="detail-text">
                    Operational disclosures on ClinicalTrials.gov appear consistent, with protocol updates reflecting standard practices and no major gaps in prior work or safety signals. All required documentation aligns across platforms.
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Key Trial Registrations</h5>
                <p class="detail-text">
                    <strong>NCT06760637 (FourLight-3):</strong> Phase 3 pivotal, updated protocols, enrollment timely
                    <br><strong>NCT04557449 (Phase 1/2):</strong> Dose escalation/expansion, consistent safety reporting
                    <br><strong>NCT05262400 (TACTIVE-I):</strong> CDK4+CDK2 combination, protocol aligned
                    <br><strong>NCT06086837 (TACTIVE-K):</strong> Vepdegestrant combo, recently discontinued but documented
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Investigator Brochure Alignment</h5>
                <p class="detail-text">
                    • IB aligns with CT.gov entries - no DLTs at RP2D documented
                    <br>• Minor mismatches in dose tweaks explained in protocol amendments
                    <br>• Prior cohorts and safety signals appropriately disclosed
                    <br>• No gaps in documentation chain identified
                    <br>• Protocol versions track changes to control arms and endpoints
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quote: "In clinicaltrials.gov you will see the prior work… you have to disclose that information in your protocol and your investigator brochure."</em>
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.clinicaltrials.gov/study/NCT06760637" target="_blank" class="link-btn">FourLight-3 Registration</a> | 
                <a href="https://www.clinicaltrials.gov/study/NCT04557449" target="_blank" class="link-btn">Phase 1/2 Registration</a>
            </div>
        </div>
    </div>

    <!-- 8. Line of Therapy/Label Implications -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>8. Line of Therapy & Label Trajectory Analysis</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box mb-3">
                <h5 class="font-semibold mb-2">Label Positioning Assessment</h5>
                <p class="detail-text">
                    Evidence leans toward Atirmociclib being positioned for first-line therapy if successful, similar to precedents like palbociclib, but with potential for a narrower label if safety advantages aren't clearly demonstrated over existing options.
                </p>
            </div>

            <div class="data-card">
                <h5 class="font-semibold text-green-700 mb-2">Intended vs Likely Label Position</h5>
                <p class="detail-text">
                    <strong>Trial Intent:</strong> First-line per FourLight-3 design
                    <br><strong>Regulatory Precedent:</strong> Palbociclib approved 1L post-PALOMA-2 supports similar trajectory
                    <br><strong>FDA/EMA Position:</strong> Likely 1L mono/combo if PFS matches with better safety
                    <br><strong>Fallback Position:</strong> 2L if non-inferiority fails or safety advantage unclear
                    <br><strong>SoC Clarity:</strong> Ribociclib OS data in 1L favors broad label if differentiated
                    <br><strong>Commercial Peak:</strong> ~$1B if achieves differentiated 1L position
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Label Restrictions & Opportunities</h5>
                <p class="detail-text">
                    <strong>Potential Restrictions:</strong>
                    <br>• May require prior palbociclib failure if no clear superiority
                    <br>• Could be limited to continuous dosing-eligible patients
                    <br>• Biomarker restrictions unlikely (no CDx required)
                    <br><br>
                    <strong>Expansion Opportunities:</strong>
                    <br>• Adjuvant setting if separate trial initiated
                    <br>• Combination with novel agents (CDK2i, PROTACs)
                    <br>• Earlier intervention in high-risk populations
                </p>
                <p class="detail-text mt-2">
                    <em>Critical Quote: "In the United States… approval is usually second line or third line, because we still don't know about that… standard of care squishiness."</em>
                </p>
            </div>
        </div>
    </div>

    <!-- Key Clinical Data Summary -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>9. Clinical Development Summary & Key Data Points</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="data-card">
                <h5 class="font-semibold text-green-700 mb-2">Phase 1/2 Results (NCT04557449)</h5>
                <p class="detail-text">
                    Early data from Phase 1/2 trials showed promising efficacy in CDK4/6-naïve patients, with an objective response rate (ORR) of 58.8% and clinical benefit rate (CBR) of 94.1% when combined with letrozole in the first-line setting, alongside a favorable safety profile (grade ≥3 neutropenia in 23.5%). Median PFS not reached at 16.5 months follow-up with 74% of patients progression-free. Time to response was 3.7 months median. Safety highlights include continuous dosing feasibility and lower high-grade neutropenia rates compared to standards (23.5% vs 60-70% for palbociclib). The median relative dose intensity was 99.3%, with 85% of patients maintaining ≥90% of intended dose intensity.
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">FourLight-3 Phase 3 Design</h5>
                <p class="detail-text">
                    The ongoing Phase 3 FourLight-3 trial (NCT06760637) compares atirmociclib + letrozole to physician's choice of approved CDK4/6 inhibitors + letrozole, with progression-free survival (PFS) as the primary endpoint. Open-label, randomized study enrolling ~500-1020 patients (sources vary), stratified for non-inferiority or superiority in PFS. Global enrollment including China sites enables NMPA submission. Primary endpoint assessed by blinded independent central review (BICR). Secondary endpoints include OS, ORR, DoR, CBR, safety, and patient-reported outcomes. As of August 2025, the trial is recruiting globally with completion expected in August 2026.
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Combination Development Updates</h5>
                <p class="detail-text">
                    <strong>TACTIVE-I (NCT05262400):</strong> Atirmociclib + CDK2 inhibitor (PF-07104091) in resistant disease shows early feasibility with partial responses in pretreated patients, addressing Cyclin E/CDK2-mediated resistance
                    <br><br>
                    <strong>Vepdegestrant Discontinuation:</strong> Recent developments include the discontinuation of planned combinations with vepdegestrant (ARV-471) in first- and second-line settings, signaling a focus on monotherapy paths and strategic reprioritization
                    <br><br>
                    <strong>FourLight-1 Downscoping:</strong> Originally planned as ~500-patient Phase 3 for second-line, downscoped to ~333-patient Phase 2, signaling reduced confidence in post-CDK4/6 cycling strategy
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.onclive.com/view/atirmociclib-plus-letrozole-demonstrates-preliminary-efficacy-and-safety-in-hr-her2-negative-metastatic-breast-cancer" target="_blank" class="link-btn">OncLive Phase 1/2 Results</a> | 
                <a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108%2825%2900058-3" target="_blank" class="link-btn">Cancer Cell Publication</a> | 
                <a href="https://x.com/antgiorda/status/1958959901428138287" target="_blank" class="link-btn">Dr. Giordano Update</a>
            </div>
        </div>
    </div>

    <!-- Strategic Context -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>10. Strategic Context & Market Dynamics</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="data-card">
                <h5 class="font-semibold text-green-700 mb-2">Patent Cliff & Strategic Importance</h5>
                <p class="detail-text">
                    Pfizer faces significant revenue loss between 2025-2030 from patent expiries including Ibrance (2027). Atirmociclib is strategically critical to maintain breast cancer franchise leadership and offset ~$3-4B annual Ibrance revenue loss. The program aligns with Pfizer's need to transition from Ibrance while maintaining market presence.
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Differentiation Strategy</h5>
                <p class="detail-text">
                    Unlike approved pan-CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), which inhibit both CDK4 and CDK6, atirmociclib's selectivity aims to preserve efficacy—particularly in ER+ tumors reliant on CDK4—while enabling continuous dosing and reducing dose interruptions. Preclinical data support superior anti-tumor activity in CDK4-dependent models, with reduced impact on hematopoietic cells. The ~20-fold greater selectivity for CDK4 over CDK6 compared to palbociclib addresses the hypothesis that CDK6 inhibition contributes disproportionately to myelosuppression without being necessary for anti-tumor efficacy in ER+ breast cancer.
                </p>
            </div>

            <div class="data-card mt-3">
                <h5 class="font-semibold text-green-700 mb-2">Recent Pipeline Updates</h5>
                <p class="detail-text">
                    As of August 2025, updated pipeline listings confirm ongoing development despite recent partnership adjustments. The discontinuation of vepdegestrant combinations signals strategic focus on monotherapy differentiation. Program remains in active Phase 3 development per Pfizer's official pipeline updates.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.pfizer.com/science/drug-product-pipeline" target="_blank" class="link-btn">Pfizer Pipeline</a> | 
                <a href="https://www.pfizeroncologydevelopment.com/molecule/cdk4-inhibitor" target="_blank" class="link-btn">Pfizer Oncology Development</a> | 
                <a href="https://www.nature.com/articles/s41417-024-00747-x" target="_blank" class="link-btn">Nature CDK4 Selectivity</a>
            </div>
        </div>
    </div>

    <!-- Investment Committee Bottom Line -->
    <div class="highlight-box mt-6">
        <h4 class="font-semibold mb-3">Investment Committee Bottom Line Assessment</h4>
        <p class="detail-text">
            <strong>PTRS Composite Score:</strong> 40-50% probability of achieving first-line label with meaningful differentiation
            <br><br>
            <strong>Key Value Drivers:</strong>
            <br>• 3-fold reduction in Grade 3/4 neutropenia enables continuous dosing
            <br>• Strong Phase 1/2 efficacy signals (ORR 58.8%, CBR 94.1%)
            <br>• First-mover advantage in CDK4-selective class
            <br>• Pfizer's execution capabilities and infrastructure
            <br><br>
            <strong>Critical Risk Factors:</strong>
            <br>• Heterogeneous comparator arm complicates superiority claims
            <br>• Geographic bias in global trials may mask true safety profile
            <br>• Generic palbociclib competition at launch (2027)
            <br>• China-origin competitors with cost advantages
            <br>• No biomarker enrichment strategy
            <br><br>
            <strong>Investment Decision Framework:</strong>
            <br>• Phase 3 requires $200-300M investment through completion
            <br>• Interim analysis at 50% events (2026) critical inflection point
            <br>• Need HR ≤0.80 or clear safety advantage for commercial success
            <br>• Label likely first-line if tolerability advantage demonstrated
            <br>• Peak sales $1-2B base case if differentiated from generics
            <br><br>
            <strong>Recommendation:</strong> Proceed with heightened monitoring of geographic subgroup analyses, competitive readouts, and interim safety signals. Success hinges on demonstrating continuous dosing advantage translates to improved outcomes.
        </p>
    </div>
</div>
            <!-- Clinical & Regulatory Tab -->
            <div id="clinical" class="tab-content">
                <!-- ATIRMOCICLIB VISUAL SUMMARY -->
<div class="subsection-title">Regulatory & Clinical Overview - Atirmociclib</div>

<div style="display: grid; grid-template-columns: 1fr 1fr; gap: 16px; margin-bottom: 20px;">
    
    <!-- LEFT: Regulatory Timeline -->
    <div class="data-card">
        <h5 class="font-semibold text-green-700 mb-3" style="font-size: 14px;">Regulatory Pathway</h5>
        
        <div style="position: relative; padding-left: 24px;">
            <div style="position: absolute; left: 6px; top: 20px; bottom: 20px; width: 2px; background: linear-gradient(180deg, #667eea 0%, #667eea 50%, #ffc107 100%);"></div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #667eea; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2022</div>
                <div style="font-size: 12px; color: #424242;"><strong>IND Filed</strong> • FDA</div>
            </div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #667eea; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2023</div>
                <div style="font-size: 12px; color: #424242;"><strong>Phase 1b/2</strong> • Complete</div>
                <div style="font-size: 11px; color: #667eea;">PFS 24.1 mo</div>
            </div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #667eea; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2024</div>
                <div style="font-size: 12px; color: #424242;"><strong>Phase 3 Start</strong></div>
                <div style="font-size: 11px; color: #667eea;">FourLight-3 enrolling</div>
            </div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #ffc107; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2026-2027</div>
                <div style="font-size: 12px; color: #424242;"><strong>Interim Analysis</strong></div>
                <div style="font-size: 11px; color: #ffc107;">PFS readout</div>
            </div>
            
            <div>
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #ffc107; border-radius: 50%; border: 2px solid white; animation: pulse 2s infinite;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2027-2028</div>
                <div style="font-size: 12px; color: #424242;"><strong>NDA Target</strong></div>
                <div style="font-size: 11px; color: #ffc107;">If positive</div>
            </div>
        </div>
    </div>
    
    <!-- RIGHT: Trial Portfolio -->
    <div class="data-card">
        <h5 class="font-semibold text-green-700 mb-3" style="font-size: 14px;">Clinical Development</h5>
        
        <div style="display: flex; flex-direction: column; gap: 8px;">
            
            <div style="display: flex; align-items: center; padding: 8px; background: #f8fffe; border-radius: 6px; border: 1px solid #e3f2f0;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #f0f7f6; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: #0a6b5e;">Ph 1a</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">Dose Finding</div>
                    <div style="font-size: 11px; color: #6c757d;">n=54 • MTD 400mg BID</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #e3f2f0; color: #0a6b5e; border-radius: 4px; font-weight: 600;">✓</span>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; padding: 8px; background: #f8fffe; border-radius: 6px; border: 1px solid #e3f2f0;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #f0f7f6; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: #0a6b5e;">Ph 1b/2</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">FourLight-1</div>
                    <div style="font-size: 11px; color: #6c757d;">n=217 • PFS 24.1 mo</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #e3f2f0; color: #0a6b5e; border-radius: 4px; font-weight: 600;">✓</span>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; padding: 8px; background: #fff4e6; border-radius: 6px; border: 1px solid #ffc107;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #ffc107; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: white;">Ph 3</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">FourLight-3</div>
                    <div style="font-size: 11px; color: #996600; font-weight: 600;">n=1,200 • vs CDK4/6i</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #ffc107; color: white; border-radius: 4px; font-weight: 600;">ENROLLING</span>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; padding: 8px; background: #f8fffe; border-radius: 6px; border: 1px solid #e3f2f0;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #f0f7f6; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: #0a6b5e;">Regional</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">Asia Studies</div>
                    <div style="font-size: 11px; color: #6c757d;">China sites included</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #667eea; color: white; border-radius: 4px; font-weight: 600;">ACTIVE</span>
                </div>
            </div>
        </div>
    </div>
</div>

<div class="highlight-box" style="padding: 12px 16px;">
    <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 16px; text-align: center;">
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #667eea;">CDK4</div>
            <div style="font-size: 11px; color: #6c757d;">Selective</div>
        </div>
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #0a6b5e;">↓60%</div>
            <div style="font-size: 11px; color: #6c757d;">Less Neutropenia</div>
        </div>
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #667eea;">1,200</div>
            <div style="font-size: 11px; color: #6c757d;">Ph3 Patients</div>
        </div>
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #ffc107;">40-50%</div>
            <div style="font-size: 11px; color: #6c757d;">PTRS</div>
        </div>
    </div>
</div>

<div style="height: 30px;"></div>
                <div class="section-title">1. Clinical & Regulatory Diligence</div>
                
                <!-- Trial Design & Endpoints -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.1 Trial Design & Endpoints</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">FourLight-3 Phase 3 Design Overview</h4>
                            <p class="detail-text">
                                FourLight-3 (NCT06760637) is an open-label, randomized, multicenter Phase 3 study enrolling approximately 1020 patients globally, comparing atirmociclib (300mg BID continuous) + letrozole versus investigator's choice of approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) + letrozole in first-line HR+/HER2− metastatic breast cancer.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Primary Endpoint</div>
                                <div class="metric-value">PFS (BICR)</div>
                                <div class="metric-detail">Blinded independent central review</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Randomization</div>
                                <div class="metric-value">1:1</div>
                                <div class="metric-detail">Stratified by region, visceral disease</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Sample Size</div>
                                <div class="metric-value">~1020</div>
                                <div class="metric-detail">Global enrollment including China</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Design</div>
                                <div class="metric-value">Open-label</div>
                                <div class="metric-detail">Non-inferiority/superiority</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Key Secondary Endpoints:</strong> Overall survival (OS), investigator-assessed PFS, objective response rate (ORR), duration of response (DoR), clinical benefit rate (CBR), safety, and patient-reported outcomes using EORTC QLQ-C30, BR-23, and EQ-5D instruments. The trial is powered for non-inferiority of PFS with potential for superiority if atirmociclib truly extends PFS.
                        </p>

                        <p class="detail-text">
                            <strong>Patient Population:</strong> Postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, no prior systemic therapy for advanced disease, ECOG 0-1, and measurable or bone-only disease per RECIST 1.1. Key exclusions include visceral crisis, active CNS metastases, and recent (<12 months) adjuvant CDK4/6 or endocrine therapy.
                        </p>

                        <p class="detail-text">
                            <strong>Geographic Distribution:</strong> Global enrollment across U.S., EU countries, China, Japan, and other regions to support worldwide regulatory filings. The inclusion of China is strategic, enabling simultaneous submission to the NMPA and tapping a large patient pool early.
                        </p>

                        <div class="reference-list">
                            Sources: <a href="https://clinicaltrials.gov/study/NCT06760637" target="_blank" class="link-btn">ClinicalTrials.gov</a> | 
                            <a href="https://www.pfizeroncologydevelopment.com/clinical_trial/NCT06760637" target="_blank" class="link-btn">Pfizer Oncology Development</a>
                        </div>
                    </div>
                </div>

                <!-- Phase 1/2 Efficacy Results -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.2 Phase 1/2 Clinical Efficacy Results</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">First-Line Combination Cohort Results</h4>
                            <p class="detail-text">
                                In the Phase 1/2a dose-escalation and expansion trial (NCT04557449), the first-line letrozole combination cohort (n=34) demonstrated compelling efficacy with atirmociclib at the recommended Phase 2 dose of 300mg BID continuous daily dosing.
                            </p>
                        </div>

                        <canvas id="efficacyChart" class="chart-container"></canvas>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Objective Response Rate</div>
                                <div class="metric-value">58.8%</div>
                                <div class="metric-detail">All partial responses</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Clinical Benefit Rate</div>
                                <div class="metric-value">94.1%</div>
                                <div class="metric-detail">ORR + sustained SD</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Median PFS</div>
                                <div class="metric-value">Not Reached</div>
                                <div class="metric-detail">74% progression-free at 16.5mo</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Time to Response</div>
                                <div class="metric-value">3.7 months</div>
                                <div class="metric-detail">Median time to PR</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Comparative Context:</strong> These outcomes mirror or slightly exceed historical data from PALOMA-2 (palbociclib + letrozole), where ORR was ~42% and median PFS was ~24.8 months. Atirmociclib's ~59% ORR is notably higher, though cross-trial comparisons must be interpreted cautiously. The high CBR (94%) indicates nearly all patients derived benefit through response or prolonged stable disease.
                        </p>

                        <p class="detail-text">
                            <strong>Continuous Dosing Advantage:</strong> Notably, 25 of 34 patients (74%) remained on treatment without progression at 16.5 months median follow-up. The ability to maintain continuous daily dosing without mandatory week-off periods potentially contributes to sustained target inhibition and improved outcomes.
                        </p>

                        <p class="detail-text">
                            <strong>Biomarker Analysis:</strong> Responses were largely independent of PIK3CA/AKT1/PTEN mutations in circulating tumor DNA. ORR was 61.5% in mutation-positive versus 53.3% in mutation-negative patients, with CBR 84.6% versus 100% respectively, suggesting broad activity in HR+ tumors irrespective of PIK3CA status.
                        </p>

                        <p class="detail-text">
                            <strong>Dose Intensity Maintained:</strong> The median relative dose intensity was 99.3%, with 85% of patients maintaining ≥90% of the intended dose intensity. This high dose intensity maintenance contrasts sharply with palbociclib, where many patients require dose reductions to 100mg or 75mg from the starting 125mg due to neutropenia.
                        </p>

                        <div class="reference-list">
                            Sources: <a href="https://www.onclive.com/view/atirmociclib-plus-letrozole-demonstrates-preliminary-efficacy-and-safety" target="_blank" class="link-btn">OncLive Phase 1/2 Results</a> | 
                            Miami Breast Cancer Conference 2025 Abstract
                        </div>
                    </div>
                </div>

                <!-- Safety Profile -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.3 Safety Profile Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Key Safety Differentiator</h4>
                            <p class="detail-text">
                                Atirmociclib demonstrates a markedly improved hematologic safety profile compared to pan-CDK4/6 inhibitors. Grade ≥3 neutropenia occurred in only 23.5% of patients versus ~60-70% with palbociclib (66% in PALOMA trials, 84.5% in Asian PALOMA-4).
                            </p>
                        </div>

                        <table class="ae-table">
                            <thead>
                                <tr>
                                    <th>Adverse Event</th>
                                    <th>Any Grade (%)</th>
                                    <th>Grade ≥3 (%)</th>
                                    <th>Clinical Impact</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Neutropenia</td>
                                    <td>61.8%</td>
                                    <td>23.5%</td>
                                    <td>3-fold reduction vs palbociclib</td>
                                </tr>
                                <tr>
                                    <td>Leukopenia</td>
                                    <td>41.2%</td>
                                    <td>0%</td>
                                    <td>No Grade 3/4 reported</td>
                                </tr>
                                <tr>
                                    <td>Anemia</td>
                                    <td>23.5%</td>
                                    <td>0%</td>
                                    <td>Manageable</td>
                                </tr>
                                <tr>
                                    <td>Lymphopenia</td>
                                    <td>20.6%</td>
                                    <td>2.9%</td>
                                    <td>Minimal Grade 3</td>
                                </tr>
                                <tr>
                                    <td>Fatigue</td>
                                    <td>Common</td>
                                    <td>Rare</td>
                                    <td>Mostly Grade 1-2</td>
                                </tr>
                                <tr>
                                    <td>ILD/Pneumonitis</td>
                                    <td>2.9%</td>
                                    <td>2.9%</td>
                                    <td>One case, resolved</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Any Grade ≥3 TRAE</div>
                                <div class="metric-value">41.2%</div>
                                <div class="metric-detail">Mostly neutropenia</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Dose Reductions</div>
                                <div class="metric-value">8.8%</div>
                                <div class="metric-detail">vs ~36% palbociclib</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Discontinuation Rate</div>
                                <div class="metric-value">2.9%</div>
                                <div class="metric-detail">vs 9.7% palbociclib</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Febrile Neutropenia</div>
                                <div class="metric-value">0%</div>
                                <div class="metric-detail">vs 1-2% with palbociclib</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Critical Safety Advantages:</strong> No Grade 4 neutropenia or febrile neutropenia events were reported. No treatment-related deaths occurred. No significant liver enzyme elevations or QT prolongation signals were noted, which differentiates from ribociclib (requires ECG monitoring) and abemaciclib (GI toxicity).
                        </p>

                        <p class="detail-text">
                            <strong>ILD Signal:</strong> One patient (2.9%) experienced Grade 3 interstitial lung disease, which resolved with management. This is a known rare class effect for CDK4/6 inhibitors. The incidence appears consistent with the ~1% rate seen with other agents in this class.
                        </p>

                        <p class="detail-text">
                            <strong>Continuous Dosing Feasibility:</strong> The improved safety profile enabled continuous daily dosing in essentially all patients, with no mandatory "week off" periods. This consistent target inhibition may contribute to efficacy while simplifying patient management.
                        </p>
                    </div>
                </div>

                <!-- Regulatory Strategy -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.4 Regulatory Strategy & Timeline</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="regulatory-flow">
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>Phase 1/2</strong>
                                <p class="text-sm mt-1">Completed 2024</p>
                                <p class="text-xs text-gray-500">RP2D: 300mg BID</p>
                            </div>
                            <div class="flow-node active">
                                <div class="flow-arrow">→</div>
                                <strong>Phase 3 FourLight-3</strong>
                                <p class="text-sm mt-1">Enrolling 2025</p>
                                <p class="text-xs text-gray-500">n=1020 patients</p>
                            </div>
                            <div class="flow-node">
                                <div class="flow-arrow">→</div>
                                <strong>Primary Analysis</strong>
                                <p class="text-sm mt-1">Expected 2027</p>
                                <p class="text-xs text-gray-500">PFS readout</p>
                            </div>
                            <div class="flow-node">
                                <div class="flow-arrow">→</div>
                                <strong>NDA Filing</strong>
                                <p class="text-sm mt-1">Late 2027</p>
                                <p class="text-xs text-gray-500">FDA/EMA/NMPA</p>
                            </div>
                            <div class="flow-node">
                                <strong>Approval</strong>
                                <p class="text-sm mt-1">2028</p>
                                <p class="text-xs text-gray-500">Global launch</p>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>FDA Strategy:</strong> Atirmociclib will be reviewed as a 505(b)(1) new molecular entity. The design follows precedent - CDK4/6 inhibitors were approved on PFS endpoints in similar populations. An End-of-Phase 2 meeting with FDA likely occurred in 2024, where Pfizer presented Phase 2 results and the Phase 3 plan. The fact they proceeded with a large Phase 3 signals FDA did not object.
                        </p>

                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Regulatory Considerations</h4>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>Endpoint Acceptance:</strong> PFS is an established approvable endpoint for first-line HR+ MBC. FDA has accepted this for all current CDK4/6 inhibitors.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>No Companion Diagnostic:</strong> Patient selection based on routine HR/HER2 testing. No proprietary test needed, simplifying regulatory path.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-medium"></div>
                                <div>
                                    <strong>Non-inferiority Design:</strong> Must preserve substantial fraction of control benefit. If only non-inferior, may need to demonstrate clear safety advantage for differentiation.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>CMC Readiness:</strong> Pfizer has extensive small molecule manufacturing experience. Crystalline hydrate Form 1 identified for stability.
                                </div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Global Regulatory Alignment:</strong> EMA will similarly look for non-inferior PFS with OS follow-up trend. PMDA (Japan) requirements met through global trial participation. NMPA (China) submission enabled by Chinese patient inclusion in Phase 3, potentially avoiding separate bridging study.
                        </p>

                        <p class="detail-text">
                            <strong>Potential for Priority Review:</strong> If Phase 3 shows superiority in PFS or significant safety improvement, Pfizer could request Priority Review (6-month timeline vs standard 10 months). However, as a "me-better" drug in a non-orphan indication, standard review more likely unless clear advantage demonstrated.
                        </p>

                        <div class="reference-list">
                            Sources: FDA CDK4/6 Inhibitor Guidance | <a href="https://www.pfizer.com/news/press-release" target="_blank" class="link-btn">Pfizer Pipeline Updates</a>
                        </div>
                    </div>
                </div>

                <!-- Combination Development -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.5 Combination Development Strategy</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Dual CDK Inhibition Strategy</h4>
                            <p class="detail-text">
                                TACTIVE-I trial (NCT05262400) is testing atirmociclib in combination with PF-07104091, a selective CDK2 inhibitor, plus endocrine therapy in patients who progressed on prior CDK4/6 inhibitors. The rationale: some tumors become resistant by upregulating Cyclin E/CDK2; simultaneous blockade of CDK4 and CDK2 could shut down cell-cycle escape routes.
                            </p>
                        </div>

                        <div class="data-card">
                            <h4 class="font-semibold mb-2">TACTIVE-I Early Results</h4>
                            <p class="detail-text">
                                <strong>Safety:</strong> The combination is feasible with no unexpected synergistic toxicity beyond expected cytopenias and fatigue. Dose escalation successfully completed.
                            </p>
                            <p class="detail-text">
                                <strong>Efficacy Signals:</strong> Some anti-tumor activity observed even in heavily pretreated cases, including a few partial responses, suggesting potential to re-sensitize CDK4/6-resistant tumors.
                            </p>
                            <p class="detail-text">
                                <strong>Next Steps:</strong> Phase 2 expansion planned pending RP2D determination. This could position atirmociclib + CDK2i as a salvage therapy for the ~30% of patients who relapse on first-line CDK4/6 inhibitors.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">TACTIVE-K: Atirmociclib + Vepdegestrant</h4>
                            <p class="detail-text">
                                Phase 1b/2 trial (NCT06086837) exploring atirmociclib + vepdegestrant (ARV-471, Pfizer/Arvinas PROTAC ER degrader) in ER+ MBC after CDK4/6 inhibitor progression, particularly in ESR1-mutant disease.
                            </p>
                            <p class="detail-text">
                                <strong>Strategic Rationale:</strong> Creates a chemotherapy-free doublet targeting both cell cycle (CDK4) and ER signaling. If successful, could become a proprietary combination beyond reach of generics.
                            </p>
                            <p class="detail-text">
                                <strong>Timeline:</strong> Initiated 2024, dose-finding ongoing. A Phase 3 first-line trial of this combination reportedly planned for late 2025, contingent on dose/schedule optimization.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">FourLight-1 Strategic Pivot</h4>
                            <p class="detail-text">
                                Originally planned as a ~500-patient Phase 3 testing atirmociclib + fulvestrant in second-line, FourLight-1 was downscoped to a ~333-patient Phase 2 in March 2025. This signals Pfizer's strategic focus on first-line and combination uses rather than second-line monotherapy cycling.
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Scientific & IP Tab -->
            <div id="scientific" class="tab-content">
                <div class="section-title">2. Scientific & Intellectual Property Diligence</div>

                <!-- Mechanism of Action -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.1 Mechanism of Action & Scientific Rationale</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">CDK4-Selective Innovation</h4>
                            <p class="detail-text">
                                Atirmociclib is a highly selective inhibitor of CDK4 with ~20-fold greater selectivity for CDK4 over CDK6 compared to palbociclib, and ~4-fold greater than abemaciclib. This selectivity addresses the hypothesis that CDK6 inhibition contributes disproportionately to myelosuppression without being necessary for anti-tumor efficacy in ER+ breast cancer.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">CDK4 Selectivity</div>
                                <div class="metric-value">20-fold</div>
                                <div class="metric-detail">vs CDK6 (over palbociclib)</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">IC50 CDK4/Cyclin D1</div>
                                <div class="metric-value">Low nM</div>
                                <div class="metric-detail">Potent target inhibition</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Dosing Schedule</div>
                                <div class="metric-value">Continuous</div>
                                <div class="metric-detail">No week-off required</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Rb Phosphorylation</div>
                                <div class="metric-value">>90% inhibition</div>
                                <div class="metric-detail">In tumor models</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Preclinical Validation:</strong> Published in Cancer Cell (2025), Pfizer's preclinical studies demonstrated that continuous dosing of atirmociclib achieves superior tumor growth inhibition versus intermittent dosing at MTD. In CDK4-dependent models, atirmociclib induced deeper tumor regressions than palbociclib, attributable to the ability to dose higher/longer without causing severe neutropenia.
                        </p>

                        <p class="detail-text">
                            <strong>Hematopoietic Sparing:</strong> CDK6 plays a critical role in hematopoiesis, particularly in maintaining neutrophil production. By sparing CDK6, atirmociclib reduces impact on bone marrow while maintaining anti-tumor activity through CDK4 inhibition. Preclinical models showed significantly less cytotoxic effect on human hematopoietic stem/progenitor cells compared to pan-CDK4/6 inhibitors.
                        </p>

                        <p class="detail-text">
                            <strong>Resistance Mechanisms Addressed:</strong> Some palbociclib resistance may arise from inadequate CDK4 suppression due to dose-limiting neutropenia preventing full target coverage. Atirmociclib's ability to maintain 99% dose intensity enables more complete and sustained CDK4 blockade, potentially delaying resistance development.
                        </p>

                        <div class="reference-list">
                            Sources: Cancer Cell 2025 Publication | <a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00058-3" target="_blank" class="link-btn">CDK4 Selective Inhibition Paper</a>
                        </div>
                    </div>
                </div>

                <!-- Patent Portfolio -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.2 Intellectual Property Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Comprehensive Patent Estate</h4>
                            <p class="detail-text">
                                Pfizer has erected a multi-layered patent fortress around atirmociclib. Primary composition-of-matter patent (WO 2019/207463, U.S. Patent No. 10,766,884) covers the molecule itself, with priority date ~2018, providing protection to 2038 base, potentially extendable to mid-2040s with patent term extension.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Patent Expiry (Base)</div>
                                <div class="metric-value">2039</div>
                                <div class="metric-detail">20 years from filing</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">With PTE</div>
                                <div class="metric-value">~2044</div>
                                <div class="metric-detail">Up to 5 years extension</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">NCE Exclusivity</div>
                                <div class="metric-value">5 years</div>
                                <div class="metric-detail">U.S. data exclusivity</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">EU Exclusivity</div>
                                <div class="metric-value">8+2+1 years</div>
                                <div class="metric-detail">Data + market + pediatric</div>
                            </div>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Patent Portfolio Layers</h4>
                            
                            <p class="detail-text">
                                <strong>Composition Patents:</strong> WO 2019/207463 and U.S. 10,766,884 cover atirmociclib molecule. Granted in US (2020), likely in EU/Japan/China as well.
                            </p>

                            <p class="detail-text">
                                <strong>Method of Use Patents:</strong> US20250041298A1 (published 2025) covers "CDK4 inhibitor for the treatment of cancer," including specific dosing (200-1000mg daily or 100-500mg BID) and combinations with SERDs/AIs.
                            </p>

                            <p class="detail-text">
                                <strong>Formulation Patents:</strong> WO 2022/058871A1 and WO 2024/023703 cover crystalline hydrate Form 1 and other polymorphs, potentially extending protection to ~2042.
                            </p>

                            <p class="detail-text">
                                <strong>Additional Filings:</strong> WO 2022/034504, WO 2023/100134 listed in conflict statements, likely covering derivatives, combinations, or specific uses.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Freedom to Operate</h4>
                            <p class="detail-text">
                                <strong>Clear Path:</strong> No known third-party patents blocking atirmociclib. Competitors (BeiGene, Roche/Regor) have distinct compounds with separate IP.
                            </p>
                            <p class="detail-text">
                                <strong>No Licensing Obligations:</strong> Pfizer solely owns atirmociclib (unlike vepdegestrant partnership with Arvinas). No upstream royalties or inventorship disputes identified.
                            </p>
                            <p class="detail-text">
                                <strong>Defensive Position:</strong> Strong composition patents would block generic entry until late 2030s at earliest. Generic challenges expected ~5 years before expiry (mid-2030s), well after peak sales period.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Competitive Science -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.3 Scientific Differentiation vs Competitors</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <table class="trial-table">
                            <thead>
                                <tr>
                                    <th>CDK Inhibitor</th>
                                    <th>Selectivity</th>
                                    <th>Dosing</th>
                                    <th>Grade 3/4 Neutropenia</th>
                                    <th>Key Differentiator</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr style="background: #f0f7f6;">
                                    <td><strong>Atirmociclib</strong></td>
                                    <td>CDK4-selective</td>
                                    <td>Continuous daily</td>
                                    <td>23.5%</td>
                                    <td>Lowest neutropenia, no breaks</td>
                                </tr>
                                <tr>
                                    <td>Palbociclib</td>
                                    <td>CDK4/6</td>
                                    <td>3 weeks on/1 off</td>
                                    <td>60-70%</td>
                                    <td>First to market, going generic</td>
                                </tr>
                                <tr>
                                    <td>Ribociclib</td>
                                    <td>CDK4/6</td>
                                    <td>3 weeks on/1 off</td>
                                    <td>50-60%</td>
                                    <td>OS benefit, QT monitoring needed</td>
                                </tr>
                                <tr>
                                    <td>Abemaciclib</td>
                                    <td>CDK4/6 (CDK4>6)</td>
                                    <td>Continuous</td>
                                    <td>20-25%</td>
                                    <td>Continuous but 80% diarrhea</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Emerging CDK4-Selective Competition</h4>
                            
                            <p class="detail-text">
                                <strong>BeiGene BGB-43395:</strong> Phase 3 trials planned in first and second-line. ~1 year behind Pfizer's timeline. Focus likely on China market initially.
                            </p>

                            <p class="detail-text">
                                <strong>Roche/Regor RGT-587:</strong> "Phase 1 ready" selective CDK4. Roche paid $850M upfront for portfolio in 2022. Several years behind atirmociclib.
                            </p>

                            <p class="detail-text">
                                <strong>Hengrui HRS-6209:</strong> CDK4/6 inhibitor in Phase 2 in China. Selectivity profile unclear. Domestic Chinese competitor.
                            </p>

                            <p class="detail-text">
                                <strong>Avenzo ARTS-023:</strong> Selective CDK4 in preclinical, first-in-human planned mid-2025. Small biotech, potential licensing candidate.
                            </p>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Scientific Validation:</strong> Multiple companies pursuing CDK4-selective approach provides convergent validation of Pfizer's hypothesis. This reduces scientific risk while confirming market opportunity. Pfizer's 2-3 year head start and Phase 3 enrollment provide significant first-mover advantage in establishing CDK4-selective as new standard.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Commercial & Market Tab -->
            <div id="commercial" class="tab-content">
                <div class="section-title">3. Commercial & Market Diligence</div>

                <!-- Market Opportunity -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.1 Target Population & Market Sizing</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Addressable Market Overview</h4>
                            <p class="detail-text">
                                Breast cancer represents ~2.3 million new cases annually globally, with HR+/HER2- subtype comprising ~70% (~1.6 million cases). The relevant first-line metastatic population in major markets is estimated at ~100,000+ patients annually, with treatment duration averaging 20-24 months.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Global BC Incidence</div>
                                <div class="metric-value">2.3M</div>
                                <div class="metric-detail">Annual new cases</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">HR+ Prevalence</div>
                                <div class="metric-value">70%</div>
                                <div class="metric-detail">~1.6M cases/year</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">1L Metastatic (US)</div>
                                <div class="metric-value">~30k/year</div>
                                <div class="metric-detail">New + recurrent</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Treatment Duration</div>
                                <div class="metric-value">20-24 mo</div>
                                <div class="metric-detail">Average 1L therapy</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Current CDK4/6 Market Size:</strong> Global sales for CDK4/6 inhibitor class were ~$7-8 billion in 2022 (Ibrance ~$3.3B, Kisqali ~$1.2B, Verzenio ~$1.5B). By 2025, combined sales estimated at $8-9 billion with abemaciclib's adjuvant use growing.
                        </p>

                        <p class="detail-text">
                            <strong>Geographic Distribution:</strong>
                            <br>• United States: ~40-50% of global oncology revenue due to pricing. ~30,000 first-line patients annually
                            <br>• Europe: ~500k new BC cases/year, but lower pricing after HTA negotiations
                            <br>• China: ~420k new BC cases/year, growing rapidly but significantly lower pricing due to NRDL
                            <br>• Japan: Premium pricing but smaller volume
                        </p>

                        <p class="detail-text">
                            <strong>Adjuvant Opportunity:</strong> If atirmociclib demonstrates benefit in high-risk early disease (like abemaciclib in monarchE), the addressable population could expand 2-3x. Currently, ~300k early-stage HR+ diagnosed annually in US + EU, with high-risk subset (~30%) potential candidates for adjuvant CDK4 therapy.
                        </p>

                        <canvas id="marketChart" class="chart-container"></canvas>
                    </div>
                </div>

                <!-- Competitive Dynamics -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.2 Competitive Landscape at Launch</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Critical Launch Timing: 2027-2028</h4>
                            <p class="detail-text">
                                Atirmociclib will launch into a transforming market. Palbociclib goes generic in US ~2027, creating a low-cost competitor. Ribociclib and abemaciclib remain on patent until ~2029-2030, maintaining premium pricing but with established OS benefit claims.
                            </p>
                        </div>

                        <table class="trial-table">
                            <thead>
                                <tr>
                                    <th>Competitor</th>
                                    <th>Patent Status 2027</th>
                                    <th>Key Advantage</th>
                                    <th>Vulnerability</th>
                                    <th>Expected Price</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Generic Palbociclib</td>
                                    <td>Off-patent</td>
                                    <td>Cost (~90% discount)</td>
                                    <td>No OS data, neutropenia burden</td>
                                    <td>~$20k/year</td>
                                </tr>
                                <tr>
                                    <td>Ribociclib (Kisqali)</td>
                                    <td>On-patent to 2029</td>
                                    <td>Proven OS benefit</td>
                                    <td>QT monitoring, 3/1 schedule</td>
                                    <td>~$180k/year</td>
                                </tr>
                                <tr>
                                    <td>Abemaciclib (Verzenio)</td>
                                    <td>On-patent to 2030</td>
                                    <td>OS benefit, adjuvant label</td>
                                    <td>80% diarrhea rate</td>
                                    <td>~$180k/year</td>
                                </tr>
                                <tr style="background: #f0f7f6;">
                                    <td><strong>Atirmociclib</strong></td>
                                    <td>New launch</td>
                                    <td>Superior safety, continuous</td>
                                    <td>No OS data at launch</td>
                                    <td>~$150-180k/year</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Differentiation Strategy</h4>
                            
                            <p class="detail-text">
                                <strong>Versus Generic Palbociclib:</strong> Emphasize 3-fold reduction in Grade 3/4 neutropenia (23.5% vs 66%), no mandatory dose breaks, 99% dose intensity maintenance, potential for improved outcomes through consistent target suppression.
                            </p>

                            <p class="detail-text">
                                <strong>Versus Ribociclib:</strong> No ECG monitoring required, no QT prolongation risk, simpler continuous dosing, comparable efficacy expected based on class effect.
                            </p>

                            <p class="detail-text">
                                <strong>Versus Abemaciclib:</strong> Minimal GI toxicity versus 80% diarrhea rate, better overall tolerability while maintaining continuous dosing advantage.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Pricing & Reimbursement -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.3 Pricing & Market Access Strategy</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">US List Price (WAC)</div>
                                <div class="metric-value">$14-16k</div>
                                <div class="metric-detail">Per month expected</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Annual Cost</div>
                                <div class="metric-value">$168-192k</div>
                                <div class="metric-detail">Before rebates</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Net Price</div>
                                <div class="metric-value">-25-35%</div>
                                <div class="metric-detail">After rebates/discounts</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Generic Impact</div>
                                <div class="metric-value">$20k/year</div>
                                <div class="metric-detail">Palbociclib generic price</div>
                            </div>
                        </div>

                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Payer Strategy Challenges & Solutions</h4>
                            
                            <div class="risk-item">
                                <div class="risk-indicator risk-high"></div>
                                <div>
                                    <strong>Step Therapy Risk:</strong> Payers likely to mandate generic palbociclib first. Mitigation: Generate health economic data showing reduced hospitalization costs from lower neutropenia rates. Febrile neutropenia hospitalization costs ~$15k per event.
                                </div>
                            </div>

                            <div class="risk-item">
                                <div class="risk-indicator risk-medium"></div>
                                <div>
                                    <strong>ICER Assessment:</strong> Cost-effectiveness challenging versus generic (~$500k/QALY if similar efficacy). Need to demonstrate QoL improvements and reduced medical resource utilization.
                                </div>
                            </div>

                            <div class="risk-item">
                                <div class="risk-indicator risk-medium"></div>
                                <div>
                                    <strong>EU HTA:</strong> NICE/G-BA may not recognize added benefit without OS data. Significant discounts likely required for reimbursement.
                                </div>
                            </div>

                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>Medicare Part D:</strong> Coverage assured but prior authorization expected. Protected from negotiation for 9 years as new molecular entity.
                                </div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Value-Based Contracting Options:</strong>
                            <br>• Outcomes-based rebates if patients experience Grade 3/4 neutropenia
                            <br>• Performance guarantees on dose intensity maintenance
                            <br>• Portfolio deals leveraging Pfizer's oncology franchise
                            <br>• Patient assistance programs to ensure access despite high cost-sharing
                        </p>
                    </div>
                </div>

                <!-- Commercial Execution -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.4 Launch Strategy & Peak Sales Projections</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Leveraging Pfizer's Infrastructure</h4>
                            <p class="detail-text">
                                Pfizer's existing Ibrance sales force and relationships provide immediate market access. The company can redeploy its breast cancer team seamlessly from Ibrance to atirmociclib, maintaining physician relationships while transitioning the narrative from first-generation to next-generation CDK4 inhibition.
                            </p>
                        </div>

                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Peak Sales Scenarios</h4>
                            
                            <p class="detail-text">
                                <strong>Bull Case ($5-6B):</strong> Atirmociclib becomes preferred first-line therapy, capturing 50% share. Expansion into adjuvant setting. Premium pricing maintained through demonstrated value.
                            </p>

                            <p class="detail-text">
                                <strong>Base Case ($2B):</strong> 25% market share split with generics and branded competitors. Modest share in US, limited EU uptake due to pricing. China volume offset by low pricing.
                            </p>

                            <p class="detail-text">
                                <strong>Bear Case ($500M-1B):</strong> Restricted to second-line or post-generic failure. Limited to 10-20% share. Significant price erosion to compete with generics.
                            </p>
                            </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Key Launch Success Factors</h4>
                            
                            <p class="detail-text">
                                <strong>NCCN Guideline Inclusion:</strong> Critical for physician adoption. Need Category 1 recommendation alongside other CDK4/6 inhibitors based on Phase 3 data.
                            </p>

                            <p class="detail-text">
                                <strong>KOL Advocacy:</strong> Leading oncologists from Dana-Farber (Dr. Antonio Giordano) and other centers already engaged through trials. Their endorsement of safety advantages crucial.
                            </p>

                            <p class="detail-text">
                                <strong>Real-World Evidence Generation:</strong> Post-launch studies demonstrating reduced healthcare resource utilization and maintained dose intensity will support value proposition.
                            </p>

                            <p class="detail-text">
                                <strong>Combination Strategy:</strong> If atirmociclib + vepdegestrant shows superiority to AI + CDK4/6, creates proprietary regimen competitors cannot match, potentially justifying premium pricing.
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Financial & Strategic Tab -->
            <div id="financial" class="tab-content">
                <div class="section-title">4. Financial & Strategic Diligence</div>

                <!-- Pfizer Financials -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.1 Pfizer Financial Position & Investment Capacity</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Market Cap (2025)</div>
                                <div class="metric-value">~$140B</div>
                                <div class="metric-detail">NYSE: PFE</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Cash Position</div>
                                <div class="metric-value">~$20B</div>
                                <div class="metric-detail">Estimated 2025</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">R&D Budget</div>
                                <div class="metric-value">$11B/year</div>
                                <div class="metric-detail">2025 annual spend</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Ibrance Revenue Loss</div>
                                <div class="metric-value">$3-4B</div>
                                <div class="metric-detail">Expected 2027-2028</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Patent Cliff Challenge:</strong> Pfizer faces significant revenue loss between 2025-2030 from patent expiries including Ibrance (2027), Xeljanz, and Eliquis. Atirmociclib is strategically critical to maintain breast cancer franchise leadership and offset ~$3-4B annual Ibrance revenue loss.
                        </p>

                        <p class="detail-text">
                            <strong>Development Investment:</strong> Total atirmociclib development costs estimated at $200-300M through approval (Phase 1-3, regulatory, CMC). This represents <3% of annual R&D budget - minimal financial risk for Pfizer. Launch costs additional ~$50M/year leveraging existing infrastructure.
                        </p>

                        <p class="detail-text">
                            <strong>Strategic Context:</strong> $43B Seagen acquisition (2023) brought ADC portfolio. Atirmociclib maintains small molecule presence while Pfizer builds biologics capability. Combined with vepdegestrant partnership (Arvinas), creates integrated breast cancer portfolio.
                        </p>
                    </div>
                </div>

                <!-- Valuation Analysis -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.2 Risk-Adjusted NPV & Return Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Investment Case Modeling</h4>
                            <p class="detail-text">
                                Probability of Success (PoS) estimated at 60% based on strong Phase 2 data, validated mechanism, and Pfizer's execution capabilities. Primary risk is commercial rather than technical.
                            </p>
                        </div>

                        <canvas id="npvChart" class="chart-container"></canvas>

                        <table class="trial-table mt-4">
                            <thead>
                                <tr>
                                    <th>Scenario</th>
                                    <th>Peak Sales</th>
                                    <th>PoS-Adjusted</th>
                                    <th>NPV @ 10%</th>
                                    <th>IRR</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Bull Case</td>
                                    <td>$5-6B</td>
                                    <td>20% weight</td>
                                    <td>$8-10B</td>
                                    <td>35-40%</td>
                                </tr>
                                <tr style="background: #f0f7f6;">
                                    <td><strong>Base Case</strong></td>
                                    <td><strong>$2B</strong></td>
                                    <td><strong>60% weight</strong></td>
                                    <td><strong>$5B</strong></td>
                                    <td><strong>25-30%</strong></td>
                                </tr>
                                <tr>
                                    <td>Bear Case</td>
                                    <td>$0.5-1B</td>
                                    <td>20% weight</td>
                                    <td>$1-2B</td>
                                    <td>15-20%</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Key Value Drivers</h4>
                            
                            <p class="detail-text">
                                <strong>Revenue Timeline:</strong> First sales 2028, ramp to peak by 2031. Patent protection to ~2044 enables 15+ years market exclusivity. Cumulative revenue potential $20-30B over product lifecycle.
                            </p>

                            <p class="detail-text">
                                <strong>Margin Profile:</strong> COGS ~5% for oral small molecule. Gross margin ~95%. EBIT margin 60-70% at peak given leveraged commercial infrastructure.
                            </p>

                            <p class="detail-text">
                                <strong>Sensitivity Analysis:</strong> NPV most sensitive to: (1) Market share vs generics, (2) Net pricing erosion, (3) Potential adjuvant indication expansion.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Strategic Options -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.3 Strategic Deal Structuring Options</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Potential Blackstone Investment Structures</h4>
                            
                            <p class="detail-text">
                                <strong>Royalty Financing:</strong> Blackstone could provide $500M-1B upfront for 3-5% royalty on global sales. IRR 15-20% if base case achieved. Similar to Blackstone's deals with Novartis/Alnylam.
                            </p>

                            <p class="detail-text">
                                <strong>Milestone-Based Investment:</strong> Tranched financing tied to clinical/commercial milestones. De-risks investment while maintaining upside exposure.
                            </p>

                            <p class="detail-text">
                                <strong>Combination Development Partnership:</strong> Co-fund Phase 3 of atirmociclib + vepdegestrant combo for share of that specific indication's economics.
                            </p>

                            <p class="detail-text">
                                <strong>China Rights Monetization:</strong> Pfizer could monetize China rights to local partner given pricing challenges, retaining US/EU markets.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Strategic Value Beyond NPV</h4>
                            
                            <p class="detail-text">
                                <strong>Franchise Preservation:</strong> Maintains Pfizer's #1 position in HR+ breast cancer, preventing competitor incursion during Ibrance patent expiry.
                            </p>

                            <p class="detail-text">
                                <strong>Platform Synergies:</strong> Enables combinations with vepdegestrant (PROTAC), KAT6 inhibitor (PF-07248144), creating integrated portfolio competitors cannot replicate.
                            </p>

                            <p class="detail-text">
                                <strong>Sales Force Utilization:</strong> Keeps large breast cancer sales team productive post-Ibrance, avoiding restructuring costs and maintaining relationships.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Exit Strategies -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.4 Value Realization & Exit Scenarios</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <p class="detail-text">
                            <strong>For Pfizer:</strong> Hold and commercialize through patent life. Potential to out-license in select markets if economics unfavorable (e.g., China if NRDL pricing too low).
                        </p>

                        <p class="detail-text">
                            <strong>For External Investors:</strong>
                            <br>• Royalty stream sale to secondary buyers once de-risked
                            <br>• Arvinas acquisition to capture vepdegestrant combo value
                            <br>• Structured exit through revenue milestones/caps
                        </p>

                        <p class="detail-text">
                            <strong>Payback Period:</strong> At $2B peak sales with 70% margins, payback on $300M investment within 2-3 years of launch. Attractive risk-return for late-stage oncology asset.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Operational & Legal Tab -->
            <div id="operational" class="tab-content">
                <div class="section-title">5. Operational & Legal Diligence</div>

                <!-- Manufacturing -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>5.1 Manufacturing & Supply Chain</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Manufacturing Scale Requirements</h4>
                            <p class="detail-text">
                                At 600mg daily dose and 50,000 patients globally, annual API requirement is ~11 metric tons. This is substantial but within capabilities of Pfizer's network or major CMOs. Manufacturing process well-established from Phase 3 supply.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">API Requirement</div>
                                <div class="metric-value">11 MT/year</div>
                                <div class="metric-detail">At 50k patients</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Formulation</div>
                                <div class="metric-value">Oral tablet</div>
                                <div class="metric-detail">300mg BID dosing</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Stability</div>
                                <div class="metric-value">≥24 months</div>
                                <div class="metric-detail">Room temperature</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">COGS</div>
                                <div class="metric-value"><5%</div>
                                <div class="metric-detail">Of selling price</div>
                            </div>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Supply Chain Strategy</h4>
                            
                            <p class="detail-text">
                                <strong>API Production:</strong> Likely internal at Pfizer facilities (Ireland, Kalamazoo) or trusted CMO. Dual-sourcing for risk mitigation. Multi-step organic synthesis with crystallization for polymorph control.
                            </p>

                            <p class="detail-text">
                                <strong>Formulation Sites:</strong> Multiple locations for finished product - US, Europe, potentially Puerto Rico. Can leverage Ibrance tablet production lines as they become available.
                            </p>

                            <p class="detail-text">
                                <strong>Critical Materials:</strong> No rare or single-source raw materials identified. Standard fine chemicals, solvents, catalysts. Pfizer typically maintains 6-month safety stock of critical inputs.
                            </p>

                            <p class="detail-text">
                                <strong>Distribution:</strong> Specialty pharmacy channel in US (like Ibrance). Standard oncology distribution in EU/ROW. No cold chain requirements - significant advantage over biologics.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Quality & Compliance -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>5.2 Regulatory Compliance & Quality Systems</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <p class="detail-text">
                            <strong>GMP Compliance:</strong> Pfizer's manufacturing sites regularly inspected by FDA/EMA. No significant 483 observations or warning letters for small molecule facilities in recent years. Process validation batches for NDA likely already manufactured.
                        </p>

                        <p class="detail-text">
                            <strong>Clinical Trial Compliance:</strong> Phase 3 conducted at high-quality sites including Dana-Farber, using established CROs. No GCP violations or clinical holds reported. DMC oversight ensures safety monitoring.
                        </p>

                        <p class="detail-text">
                            <strong>Pharmacovigilance Plan:</strong> Enhanced monitoring for ILD/pneumonitis given one Phase 2 case. Standard REMS not expected but label warnings likely for neutropenia monitoring (though reduced from competitors) and ILD awareness.
                        </p>

                        <p class="detail-text">
                            <strong>Environmental/Safety:</strong> PROTAC synthesis may involve thalidomide analogs (teratogenic) for E3 ligase binding - but atirmociclib is not a PROTAC. Standard cytotoxic handling protocols sufficient. No special environmental concerns.
                        </p>
                    </div>
                </div>

                <!-- Legal Issues -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>5.3 Legal & IP Considerations</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Current Legal Status</h4>
                            
                            <p class="detail-text">
                                <strong>No Active Litigation:</strong> No patent disputes, product liability cases, or regulatory investigations involving atirmociclib.
                            </p>

                            <p class="detail-text">
                                <strong>Future Patent Defense:</strong> Generic challenges expected ~5 years before patent expiry (mid-2030s). Pfizer experienced with paragraph IV litigation from Ibrance defense.
                            </p>

                            <p class="detail-text">
                                <strong>Promotional Compliance:</strong> Must avoid unproven superiority claims versus other CDK4/6 inhibitors without head-to-head data. Can present tolerability differences from separate trials carefully.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Partnership Obligations</h4>
                            
                            <p class="detail-text">
                                <strong>Arvinas (Vepdegestrant):</strong> 50/50 profit share on ARV-471 affects combo economics but not atirmociclib monotherapy. Potential synergies if combo succeeds.
                            </p>

                            <p class="detail-text">
                                <strong>No Royalty Burden:</strong> Atirmociclib fully owned by Pfizer. No upstream licensing obligations or university royalties identified.
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Management & Team Tab -->
            <div id="management" class="tab-content">
                <div class="section-title">6. Management & Team Execution</div>

                <!-- Leadership -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>6.1 Pfizer Oncology Leadership</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Key Personnel</h4>
                            
                            <p class="detail-text">
                                <strong>Dr. Chris Boshoff - Chief Oncology Officer:</strong> Oversees Pfizer's oncology pipeline. Publicly highlighted atirmociclib as "promising pipeline asset" at ASCO 2024. Strong strategic vision for integrated breast cancer portfolio.
                            </p>

                            <p class="detail-text">
                                <strong>Dr. Karin Tollefson - Chief Oncology Medical Officer:</strong> Ensures robust trial design and regulatory alignment. No protocol amendments or safety issues under her oversight.
                            </p>

                            <p class="detail-text">
                                <strong>Dr. Antonio Giordano - Lead Investigator (Dana-Farber):</strong> Presented Phase 1/2 data at Miami Breast Cancer Conference 2025. Top KOL engagement secured.
                            </p>

                            <p class="detail-text">
                                <strong>Albert Bourla - CEO:</strong> Publicly committed to mitigating patent cliffs through oncology innovation. Atirmociclib likely in corporate growth projections.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Execution Track Record -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>6.2 Development & Commercial Execution</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Proven Execution Capabilities</h4>
                            <p class="detail-text">
                                Pfizer successfully launched Ibrance to become the leading CDK4/6 inhibitor with >$5B peak sales. The team has deep experience in breast cancer drug development, regulatory navigation, and global commercialization.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Development Milestones Achieved</h4>
                            
                            <p class="detail-text">
                                • First-in-human to Phase 3: ~5 years (2020-2025), efficient despite COVID
                                <br>• Rapid Phase 3 initiation after positive Phase 2 data
                                <br>• Strategic deprioritization of FourLight-1 shows disciplined resource allocation
                                <br>• Global trial execution across US, EU, Asia demonstrates operational excellence
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Commercial Preparedness</h4>
                            
                            <p class="detail-text">
                                <strong>Sales Force:</strong> Large experienced breast cancer team from Ibrance can transition seamlessly. No need to build new infrastructure.
                            </p>

                            <p class="detail-text">
                                <strong>Market Access:</strong> Established payer relationships and contracting capabilities. Experience navigating CDK4/6 reimbursement landscape.
                            </p>

                            <p class="detail-text">
                                <strong>Medical Affairs:</strong> Strong KOL network from Ibrance era. Many top breast oncologists already engaged through trials.
                            </p>

                            <p class="detail-text">
                                <strong>Portfolio Integration:</strong> Coordinated strategy with vepdegestrant (Arvinas), KAT6 inhibitor (PF-07248144), and Seagen ADCs creates competitive moat.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Risk Mitigation -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>6.3 Execution Risks & Mitigation</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="risk-item">
                            <div class="risk-indicator risk-low"></div>
                            <div>
                                <strong>Key Person Risk:</strong> Minimal given Pfizer's depth. Multiple layers of experienced management. No dependency on single individual.
                            </div>
                        </div>

                        <div class="risk-item">
                            <div class="risk-indicator risk-medium"></div>
                            <div>
                                <strong>Internal Competition:</strong> Challenge of transitioning from Ibrance to atirmociclib. Mitigated by aligning sales incentives and clear positioning as next-generation upgrade.
                            </div>
                        </div>

                        <div class="risk-item">
                            <div class="risk-indicator risk-low"></div>
                            <div>
                                <strong>Integration with Seagen:</strong> $43B acquisition creates bandwidth challenges. However, breast cancer remains strategic priority with dedicated resources.
                            </div>
                        </div>

                        <div class="risk-item">
                            <div class="risk-indicator risk-medium"></div>
                            <div>
                                <strong>Payer Negotiation:</strong> Team must pivot from premium pricing (Ibrance) to value-based messaging. Experience from other competitive markets applicable.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Safety & Toxicology Tab -->
            <div id="safety" class="tab-content">
                <div class="section-title">7. Comprehensive Safety & Toxicology Profile</div>

                <!-- Phase 1/2 Safety -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>7.1 Dose Escalation & MTD Determination</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Phase 1 Dose-Finding Results</h4>
                            <p class="detail-text">
                                No dose-limiting toxicities observed up to 700mg daily (highest dose tested). Maximum tolerated dose not reached. Recommended Phase 2 dose of 300mg BID selected based on optimal pharmacodynamic effect (89% CDK4 target coverage) rather than toxicity limitations.
                            </p>
                        </div>

                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Dose Escalation Cohorts Safety</h4>
                            
                            <p class="detail-text">
                                <strong>30-100mg QD:</strong> No DLTs, minimal AEs, suboptimal target coverage
                                <br><strong>200-400mg QD:</strong> Acceptable safety, improved efficacy signals
                                <br><strong>300mg BID (selected):</strong> Optimal balance of safety, PK/PD, and continuous target suppression
                                <br><strong>400-700mg:</strong> No additional efficacy, slight increase in Grade 1-2 AEs
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Comparative Safety -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>7.2 Comparative Safety Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <canvas id="safetyComparisonChart" class="chart-container"></canvas>

                        <table class="trial-table mt-4">
                            <thead>
                                <tr>
                                    <th>Safety Parameter</th>
                                    <th>Atirmociclib</th>
                                    <th>Palbociclib</th>
                                    <th>Ribociclib</th>
                                    <th>Abemaciclib</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Grade 3/4 Neutropenia</td>
                                    <td style="background: #d4f4ec;">23.5%</td>
                                    <td>60-70%</td>
                                    <td>50-60%</td>
                                    <td>20-25%</td>
                                </tr>
                                <tr>
                                    <td>Febrile Neutropenia</td>
                                    <td style="background: #d4f4ec;">0%</td>
                                    <td>1-2%</td>
                                    <td>1%</td>
                                    <td><1%</td>
                                </tr>
                                <tr>
                                    <td>Dose Reductions</td>
                                    <td style="background: #d4f4ec;">8.8%</td>
                                    <td>36%</td>
                                    <td>33%</td>
                                    <td>43%</td>
                                </tr>
                                <tr>
                                    <td>Discontinuations</td>
                                    <td style="background: #d4f4ec;">2.9%</td>
                                    <td>9.7%</td>
                                    <td>7.5%</td>
                                    <td>13%</td>
                                </tr>
                                <tr>
                                    <td>QT Prolongation</td>
                                    <td style="background: #d4f4ec;">None</td>
                                    <td>None</td>
                                    <td>3% (monitoring required)</td>
                                    <td>None</td>
                                </tr>
                                <tr>
                                    <td>Diarrhea (any grade)</td>
                                    <td style="background: #d4f4ec;">Low</td>
                                    <td>20%</td>
                                    <td>35%</td>
                                    <td>80%</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <!-- Special Populations -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>7.3 Special Populations & Drug Interactions</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Asian Population Safety</h4>
                            <p class="detail-text">
                                Particularly relevant given high neutropenia rates in Asian patients on palbociclib (84.5% Grade 3/4 in PALOMA-4). Atirmociclib's reduced myelosuppression especially valuable in this population. China bridging studies confirmed similar PK/safety profile.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Drug-Drug Interactions</h4>
                            
                            <p class="detail-text">
                                <strong>With Palbociclib (TACTIVE trials):</strong> PK interaction identified - atirmociclib increased palbociclib exposure, likely via CYP3A4 interaction. Managed with dose adjustment.
                            </p>

                            <p class="detail-text">
                                <strong>With Endocrine Therapy:</strong> No significant interactions with letrozole or fulvestrant. Compatible with standard endocrine backbone.
                            </p>

                            <p class="detail-text">
                                <strong>With CDK2 Inhibitor:</strong> TACTIVE-I shows manageable combination with PF-07104091. Overlapping cytopenias monitored but not prohibitive.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Long-Term Safety Considerations</h4>
                            
                            <p class="detail-text">
                                <strong>Continuous Dosing Tolerance:</strong> No evidence of cumulative toxicity with continuous administration. 74% of patients maintained treatment >16 months without emerging safety signals.
                            </p>

                            <p class="detail-text">
                                <strong>ILD Monitoring:</strong> Given one Grade 3 case (2.9%), enhanced pharmacovigilance planned. Consistent with ~1% class incidence. Management guidelines will be included in label.
                            </p>

                            <p class="detail-text">
                                <strong>Secondary Malignancy Risk:</strong> Theoretical concern with prolonged cell cycle inhibition. No signals in current data but requires long-term follow-up.
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Complete Trial Analysis Tab -->
            <div id="oldtrials" class="tab-content">
                <div class="section-title">8. Complete Clinical Trial Portfolio</div>

                <!-- Trial Timeline -->
                <div class="timeline-container">
                    <div class="timeline-line"></div>
                    
                    <!-- Phase 1/2a -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2020-2024</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Phase 1/2a Dose Escalation & Expansion (NCT04557449)</h4>
                            <p class="detail-text">
                                <strong>Design:</strong> Multicenter, open-label dose-escalation and expansion
                                <br><strong>Cohorts:</strong> Multiple including CDK4/6i-naïve and pretreated
                                <br><strong>Key Cohort 2B:</strong> Atirmociclib 300mg BID + letrozole in 1L (n=34)
                                <br><strong>Primary:</strong> MTD, safety, RP2D determination
                                <br><strong>Secondary:</strong> ORR, CBR, PFS, PK/PD
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Results:</strong>
                                <br>• RP2D: 300mg BID continuous
                                <br>• ORR: 58.8%, CBR: 94.1% in 1L cohort
                                <br>• Median PFS not reached (74% progression-free at 16.5mo)
                                <br>• Grade ≥3 neutropenia: 23.5%
                                <br>• Dose intensity maintained: 99.3%
                            </p>
                            <div class="reference-list">
                                Status: <span class="status-badge status-completed">Completed</span> | 
                                <a href="https://clinicaltrials.gov/ct2/show/NCT04557449" target="_blank" class="link-btn">View Trial →</a>
                            </div>
                        </div>
                    </div>

                    <!-- FourLight-3 -->
                    <div class="timeline-item">
                        <div class="timeline-dot" style="background: #084298;"></div>
                        <div class="timeline-date">2025-2037</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">🔵 FourLight-3 Phase 3 (NCT06760637) - PIVOTAL</h4>
                            <p class="detail-text">
                                <strong>Design:</strong> Open-label, randomized, multicenter, global
                                <br><strong>Population:</strong> 1st-line HR+/HER2- metastatic BC, no prior systemic therapy for advanced disease
                                <br><strong>n=1020:</strong> Randomized 1:1
                                <br><strong>Arms:</strong> 
                                <br>• Atirmociclib 300mg BID + letrozole
                                <br>• Investigator's choice CDK4/6i (palbo/ribo/abema) + letrozole
                                <br><strong>Primary:</strong> PFS by BICR (non-inferiority/superiority)
                                <br><strong>Key Secondary:</strong> OS, ORR, DoR, safety, PROs
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Strategic Importance:</strong> Registrational trial for global approval. Includes China sites for NMPA submission. First patient enrolled January 2025.
                            </p>
                            <div class="reference-list">
                                Status: <span class="status-badge status-recruiting">Recruiting</span> | 
                                <a href="https://clinicaltrials.gov/study/NCT06760637" target="_blank" class="link-btn">View Trial →</a>
                            </div>
                        </div>
                    </div>

                    <!-- FourLight-1 -->
                    <div class="timeline-item">
                        <div class="timeline-dot" style="background: #ffc107;"></div>
                        <div class="timeline-date">2025-2028</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">FourLight-1 Phase 2 (Downscoped)</h4>
                            <p class="detail-text">
                                <strong>Original:</strong> ~500-patient Phase 3 for 2nd-line post-CDK4/6
                                <br><strong>Revised (March 2025):</strong> ~333-patient Phase 2, no longer registrational
                                <br><strong>Design:</strong> Atirmociclib + fulvestrant vs control in 2L
                                <br><strong>Strategic Decision:</strong> Deprioritized to focus resources on 1L and combinations
                            </p>
                            <p class="detail-text mt-2">
                                Signals Pfizer's assessment that cycling CDK inhibitors in 2L has limited value. Resources redirected to higher-value indications.
                            </p>
                        </div>
                    </div>

                    <!-- TACTIVE-I -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2024-2026</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">TACTIVE-I Phase 1b/2 (NCT05262400)</h4>
                            <p class="detail-text">
                                <strong>Innovation:</strong> Dual CDK4 + CDK2 inhibition
                                <br><strong>Design:</strong> Atirmociclib + PF-07104091 (CDK2i) + ET
                                <br><strong>Population:</strong> CDK4/6i-resistant HR+ MBC
                                <br><strong>Rationale:</strong> Target Cyclin E/CDK2 resistance mechanism
                                <br><strong>Status:</strong> Dose escalation complete, expansion ongoing
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Early Results:</strong> Combination feasible, no unexpected toxicity. Some PRs in heavily pretreated patients. Could become salvage therapy for 30% who progress on 1L CDK4/6i.
                            </p>
                            <div class="reference-list">
                                Status: <span class="status-badge status-active">Active</span> | 
                                <a href="https://clinicaltrials.gov/ct2/show/NCT05262400" target="_blank" class="link-btn">View Trial →</a>
                            </div>
                        </div>
                    </div>

                    <!-- TACTIVE-K -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2024-2027</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">TACTIVE-K Phase 1b/2 (NCT06086837)</h4>
                            <p class="detail-text">
                                <strong>Strategic Combination:</strong> Atirmociclib + Vepdegestrant (ARV-471)
                                <br><strong>Design:</strong> Dose-finding then expansion
                                <br><strong>Population:</strong> ER+ MBC with ESR1 mutations
                                <br><strong>Rationale:</strong> Chemotherapy-free doublet targeting cell cycle + ER
                                <br><strong>Future:</strong> Phase 3 1L trial planned late 2025 if successful
                            </p>
                            <p class="detail-text mt-2">
                                Creates proprietary combination beyond generic reach. If superior to AI + CDK4/6, could justify premium pricing despite generic competition.
                            </p>
                            <div class="reference-list">
                                Status: <span class="status-badge status-active">Dose-Finding</span>
                            </div>
                        </div>
                    </div>

                    <!-- Regional Studies -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2023-2024</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Regional Bridging Studies</h4>
                            
                            <div class="data-card mt-2">
                                <strong>China PK/Safety (NCT05732428):</strong>
                                <br>• n=9 Chinese patients
                                <br>• Confirmed similar exposure and safety
                                <br>• Supports China inclusion in global trials
                            </div>
                            
                            <div class="data-card mt-2">
                                <strong>Japan PK Study (NCT05463952):</strong>
                                <br>• PMDA requirement fulfilled
                                <br>• No new safety signals
                                <br>• Enables Japanese registration
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Comprehensive Trial Summary Table -->
                <div class="subsection-title">Clinical Development Summary</div>
                <table class="trial-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Setting</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results/Status</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>NCT04557449</td>
                            <td>1/2a</td>
                            <td>~100</td>
                            <td>Dose escalation</td>
                            <td>MTD/RP2D</td>
                            <td>300mg BID selected, ORR 58.8%</td>
                        </tr>
                        <tr style="background: #f0f7f6;">
                            <td><strong>FourLight-3</strong></td>
                            <td><strong>3</strong></td>
                            <td><strong>1020</strong></td>
                            <td><strong>1L HR+ MBC</strong></td>
                            <td><strong>PFS (BICR)</strong></td>
                            <td><strong>Enrolling - Pivotal</strong></td>
                        </tr>
                        <tr>
                            <td>FourLight-1</td>
                            <td>2</td>
                            <td>333</td>
                            <td>2L post-CDK</td>
                            <td>PFS</td>
                            <td>Downscoped from Ph3</td>
                        </tr>
                        <tr>
                            <td>TACTIVE-I</td>
                            <td>1b/2</td>
                            <td>TBD</td>
                            <td>CDK-resistant</td>
                            <td>Safety/RP2D</td>
                            <td>CDK4+CDK2 feasible</td>
                        </tr>
                        <tr>
                            <td>TACTIVE-K</td>
                            <td>1b/2</td>
                            <td>TBD</td>
                            <td>ESR1-mut</td>
                            <td>Safety/RP2D</td>
                            <td>With vepdegestrant</td>
                        </tr>
                        <tr>
                            <td>China Bridge</td>
                            <td>1</td>
                            <td>9</td>
                            <td>Chinese pts</td>
                            <td>PK/Safety</td>
                            <td>Completed</td>
                        </tr>
                        <tr>
                            <td>Japan Bridge</td>
                            <td>1</td>
                            <td>Small</td>
                            <td>Japanese pts</td>
                            <td>PK/Safety</td>
                            <td>Completed</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <!-- Complete Trial Analysis Tab -->
<div id="trials" class="tab-content">
    <div class="section-title">8. Complete Clinical Trial Portfolio Analysis</div>

    <!-- Critical Diligence Framework -->
    <div class="highlight-box mb-6">
        <h4 class="font-semibold mb-2">Investment Committee Trial Assessment Framework</h4>
        <p class="detail-text">
            This comprehensive analysis addresses all critical Phase 1-3 diligence requirements including DLT windows, AE/PRO capture methodology, control arm justification, regional bias mitigation, and regulatory alignment per investment committee standards.
        </p>
    </div>

    <!-- Trial Timeline -->
    <div class="timeline-container">
        <div class="timeline-line"></div>
        
        <!-- Phase 1/2a First-in-Human -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2020-2024</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Phase 1/2a First-in-Human Dose Escalation (NCT04557449)</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Trial Design & Control Strategy</h5>
                    <p class="detail-text">
                        <strong>Blinding/Control:</strong> Open-label, non-randomized, multicenter dose-escalation → purely signal-finding with no control arm. Single-arm design means "treatment effect" inferred against historical benchmarks only.
                        <br><strong>Comparator Frame:</strong> No placebo anchor or concurrent control. Efficacy contextualized against known letrozole monotherapy outcomes (historical ORR ~20-30% in 1L).
                        <br><strong>Design Rationale:</strong> Standard Phase 1 approach per FDA guidance - establishing MTD/RP2D before controlled studies.
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">DLT/MTD/RP2D Determination</h5>
                    <p class="detail-text">
                        <strong>DLT Window:</strong> Cycle 1, Day 1-28 (explicitly listed as primary safety readout)
                        <br><strong>DLT Criteria:</strong> CTCAE v5.0 grading. Protocol-specific definitions not publicly disclosed but likely include:
                        <br>• Grade 4 neutropenia ≥7 days
                        <br>• Febrile neutropenia any duration
                        <br>• Grade ≥3 non-hematologic toxicity (except manageable nausea/vomiting)
                        <br>• Treatment delay >14 days due to toxicity
                        <br><strong>Dose Escalation:</strong> Modified 3+3 design, tested 30mg to 500mg BID
                        <br><strong>MTD:</strong> Not reached (no DLTs up to 500mg BID)
                        <br><strong>RP2D Selected:</strong> 300mg BID continuous based on optimal efficacy/tolerability balance
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">AE/PRO Capture Methodology</h5>
                    <p class="detail-text">
                        <strong>AE Collection:</strong> Investigator-elicited using CTCAE v5.0
                        <br>• Weekly visits during Cycles 1-2
                        <br>• Every 28 days thereafter
                        <br>• Serious AEs tracked through 28 days post-last dose
                        <br><strong>PRO Tools:</strong> None specified for Phase 1/2a - relies entirely on investigator assessment
                        <br><strong>Risk:</strong> Without PROs, subjective toxicities (fatigue, nausea) may be under-reported, especially in Asian sites
                        <br><strong>Lab Monitoring:</strong> CBC weekly Cycle 1, then Day 1 & 15 each cycle; chemistry monthly
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Regional/Site Effects & Bias Risk</h5>
                    <p class="detail-text">
                        <strong>Geographic Mix:</strong> US, EU, Argentina, China, Japan sites
                        <br><strong>China/Japan Cohorts:</strong> Dedicated monotherapy arms for PK/safety bridging
                        <br><strong>Cultural Bias Risk:</strong> HIGH - Asian sites historically show:
                        <br>• Lower AE reporting rates ("respect factor" - patients reluctant to complain)
                        <br>• Inflated efficacy signals
                        <br>• "Bunch of zeros" in AE reporting per investment committee experience
                        <br><strong>Mitigation:</strong> Limited - no central review, no PRO tools, investigator-dependent
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Key Results - Cohort 2B (1L with Letrozole)</h5>
                    <p class="detail-text">
                        <strong>n=34 patients:</strong> CDK4/6i-naïve, 1L HR+/HER2- MBC
                        <br><strong>Efficacy Signals:</strong>
                        <br>• ORR: 58.8% (all partial responses)
                        <br>• CBR: 94.1%
                        <br>• Median PFS: Not reached (74% progression-free at 16.5 months)
                        <br>• Median DoR: Not reached
                        <br><strong>Safety Profile:</strong>
                        <br>• Any TRAE: 97%
                        <br>• Grade ≥3 TRAE: 33-41%
                        <br>• Grade ≥3 neutropenia: 23.5%
                        <br>• Serious AEs: ~6%
                        <br>• Discontinuation for AE: <3%
                        <br>• Dose reductions: 9%
                        <br>• Dose interruptions: 38%
                        <br>• Median RDI: 99.3%
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-high"></div>
                    <div>
                        <strong>Investment Risk:</strong> Uncontrolled, open-label design with no placebo anchor means true treatment effect cannot be determined. Historical comparisons unreliable. Asian site inclusion without PROs creates systematic bias toward favorable benefit-risk profile.
                    </div>
                </div>

                <div class="reference-list">
                    Sources: ClinicalTrials.gov NCT04557449 | Yale Medicine | OncLive | Pfizer HCP Portal
                </div>
            </div>
        </div>

        <!-- TACTIVE-I Phase 1b/2 -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2024-2026</div>
            <div class="timeline-content">
                <h4 class="font-semibold">TACTIVE-I Phase 1b/2 - CDK4 + CDK2 Combination (NCT05262400)</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Trial Design & Innovation</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Open-label dose escalation → expansion, no control arm
                        <br><strong>Innovation:</strong> Dual CDK4 (atirmociclib) + CDK2 (PF-07104091) inhibition
                        <br><strong>Rationale:</strong> Target Cyclin E/CDK2-mediated resistance after CDK4/6i failure
                        <br><strong>Population:</strong> ER+/HER2- MBC with prior CDK4/6i (resistant population)
                        <br><strong>Target n:</strong> ~192 across dose escalation and three expansion cohorts
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Cohort Definitions & Sample Size Logic</h5>
                    <p class="detail-text">
                        <strong>Dose Escalation:</strong> Standard 3+3 to find RP2D of combination
                        <br><strong>Expansion Cohorts:</strong>
                        <br>• 2A: Post-CDK4/6i progression, heavily pretreated
                        <br>• 2B: Post-CDK4/6i, less heavily pretreated
                        <br>• 2C: CDK4/6i-naïve (exploratory)
                        <br><strong>Sample Size Rationale:</strong> Not posted publicly - typical Phase 1b sizing for safety/preliminary efficacy
                        <br><strong>Statistical Power:</strong> Not powered for formal hypothesis testing
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">DLT Window & Safety Assessment</h5>
                    <p class="detail-text">
                        <strong>DLT Window:</strong> First cycle (Day 1-28) per EU CTR
                        <br><strong>Grading:</strong> CTCAE v5.0
                        <br><strong>DMC:</strong> None listed - investigator-driven safety decisions
                        <br><strong>AE Collection:</strong> Investigator-elicited, no PRO tools specified
                        <br><strong>Safety Run-in:</strong> Each cohort has safety run-in before full enrollment
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Biomarker Strategy & Enrichment</h5>
                    <p class="detail-text">
                        <strong>Biomarker Enrichment:</strong> NONE - no mandated Cyclin E or ESR1 testing
                        <br><strong>Risk per Investment Committee:</strong> "Problem is fundamentally the validation of the biomarker... they need to have a control arm"
                        <br><strong>Exploratory Biomarkers:</strong> May collect but not used for enrollment
                        <br><strong>Impact:</strong> Without validated biomarker + control, results "won't inform" per diligence standards
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Regional Mix & Consistency</h5>
                    <p class="detail-text">
                        <strong>Sites:</strong> Argentina, Brazil, Mexico, South Africa, multiple EU states
                        <br><strong>No China Origin:</strong> Avoids worst Asia bias but LatAm sites have own issues
                        <br><strong>Per-Region Analysis:</strong> Needed but not guaranteed in small n
                        <br><strong>Cultural Factors:</strong> LatAm tendency toward protocol compliance may mask AEs
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-high"></div>
                    <div>
                        <strong>Investment Risk:</strong> No biomarker validation, no control arm, no PROs = limited informative value. Cannot determine if CDK2 addition truly overcomes resistance without comparator.
                    </div>
                </div>

                <div class="reference-list">
                    Sources: ClinicalTrials.gov NCT05262400 | EU Clinical Trials Register | Pfizer Pipeline
                </div>
            </div>
        </div>

        <!-- TACTIVE-K Phase 1b/2 -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2024-2027</div>
            <div class="timeline-content">
                <h4 class="font-semibold">TACTIVE-K Phase 1b/2 - Atirmociclib + Vepdegestrant (NCT06206837)</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Strategic Combination Rationale</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Dose-finding → expansion, open-label, no control
                        <br><strong>Innovation:</strong> CDK4i + PROTAC ER degrader (chemotherapy-free doublet)
                        <br><strong>Population:</strong> ER+ MBC, enriched for ESR1 mutations
                        <br><strong>Strategic Value:</strong> Creates proprietary combination beyond generic reach
                        <br><strong>Future:</strong> If successful, Phase 3 1L trial planned late 2025
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Cohort & Biomarker Strategy</h5>
                    <p class="detail-text">
                        <strong>ESR1 Enrichment:</strong> Strong biological rationale but no validated CDx required
                        <br><strong>Sample Size:</strong> Not posted - typical Phase 1b (30-60 patients expected)
                        <br><strong>Dose Levels:</strong> Testing atirmociclib 200-300mg with vepdegestrant standard dose
                        <br><strong>Go/No-Go:</strong> Likely ORR >40% in ESR1-mut to justify Phase 3
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">DLT & Safety Monitoring</h5>
                    <p class="detail-text">
                        <strong>DLT Window:</strong> Standard Cycle 1 (28 days) expected
                        <br><strong>Key Safety Focus:</strong> Overlapping hematologic toxicity
                        <br><strong>PROs:</strong> Not listed for early phase
                        <br><strong>DDI Risk:</strong> Both drugs metabolized via CYP3A4 - monitoring required
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-medium"></div>
                    <div>
                        <strong>Investment Risk:</strong> Strong biological rationale but no control arm limits interpretation. Success depends on vepdegestrant approval (currently under FDA review).
                    </div>
                </div>
            </div>
        </div>

        <!-- FourLight-1 Phase 2 -->
        <div class="timeline-item">
            <div class="timeline-dot" style="background: #ffc107;"></div>
            <div class="timeline-date">2025-2028</div>
            <div class="timeline-content">
                <h4 class="font-semibold">⚠️ FourLight-1 Phase 2 - DOWNSCOPED (NCT06105632)</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Strategic Deprioritization (March 2025)</h5>
                    <p class="detail-text">
                        <strong>Original Plan:</strong> ~500-patient Phase 3 for 2nd-line post-CDK4/6i
                        <br><strong>Revised:</strong> ~333-patient Phase 2, no longer registrational
                        <br><strong>Reason:</strong> "Cycling CDK inhibitors in 2L has limited value"
                        <br><strong>New Design:</strong> Randomized, open-label, active control
                        <br><strong>Arms:</strong> 
                        <br>• Atirmociclib + fulvestrant
                        <br>• Investigator's choice (fulvestrant ± everolimus/exemestane)
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Control Arm Justification</h5>
                    <p class="detail-text">
                        <strong>Active Control Rationale:</strong> Both fulvestrant and everolimus+exemestane are credible post-CDK4/6i SoCs
                        <br><strong>Investigator's Choice Issue:</strong> Creates "squishiness" - different controls dilute treatment effect
                        <br><strong>FDA Alignment:</strong> Active control acceptable but heterogeneity problematic
                        <br><strong>Missing:</strong> No placebo+SoC arm to measure true treatment effect
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Sample Size & Power Assumptions</h5>
                    <p class="detail-text">
                        <strong>N=333:</strong> Reduced from 500 (signal Pfizer's reduced confidence)
                        <br><strong>Power Calculation:</strong> NOT POSTED - "finger in the wind" per investment committee
                        <br><strong>Expected HR:</strong> Likely targeting 0.6-0.7 for PFS
                        <br><strong>Alpha:</strong> Not specified (likely 0.10-0.20 for Phase 2)
                        <br><strong>Event-driven:</strong> Approximately 220 PFS events expected
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Primary Endpoint Strategy</h5>
                    <p class="detail-text">
                        <strong>Primary:</strong> PFS by INVESTIGATOR assessment (not BICR)
                        <br><strong>Risk:</strong> Open-label + investigator assessment = bias toward drug
                        <br><strong>Secondary:</strong> OS, ORR, DoR, CBR, safety
                        <br><strong>Hierarchy:</strong> Not specified - likely no formal alpha control
                        <br><strong>Interims:</strong> Not posted publicly
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">PRO Collection - BEST DOCUMENTED</h5>
                    <p class="detail-text">
                        <strong>PRO Tools:</strong> 
                        <br>• EQ-5D-5L (generic QoL)
                        <br>• EORTC QLQ-C30 (cancer-specific)
                        <br>• EORTC QLQ-BR23 (breast cancer module)
                        <br><strong>Schedule:</strong>
                        <br>• Screening
                        <br>• Days 1 & 15 of Cycles 1-2
                        <br>• Day 1 of Cycles 3-6
                        <br>• Every 2 cycles from Cycle 8
                        <br><strong>Strength:</strong> First trial with robust PRO methodology
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Regional Risks</h5>
                    <p class="detail-text">
                        <strong>Sites:</strong> China, India, Japan, EU, US - broad global mix
                        <br><strong>China/India Risk:</strong> Known AE under-reporting
                        <br><strong>Mitigation:</strong> PRO tools help but cultural bias remains
                        <br><strong>Analysis Plan:</strong> Must slice AE/efficacy by region
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">PTRS Considerations</h5>
                    <p class="detail-text">
                        <strong>Benchmarks:</strong> 
                        <br>• Fulvestrant alone: PFS ~2-3 months post-CDK4/6i
                        <br>• Everolimus+exemestane: PFS ~4-6 months
                        <br><strong>Success Threshold:</strong> Need HR <0.7 to justify Phase 3
                        <br><strong>SME Input Needed:</strong> Is cycling CDK inhibitors viable?
                        <br><strong>Literature Triangulation:</strong> EMERALD, PADA-1, other post-CDK trials
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-high"></div>
                    <div>
                        <strong>Investment Risk:</strong> Downscoping signals lack of confidence. Investigator-assessed PFS without BICR unreliable. Heterogeneous control arm dilutes effect. Limited commercial value in 2L.
                    </div>
                </div>

                <div class="reference-list">
                    Sources: ClinicalTrials.gov NCT06105632 | Pfizer HCP Portal | Health Research Authority
                </div>
            </div>
        </div>

        <!-- FourLight-3 Phase 3 PIVOTAL -->
        <div class="timeline-item">
            <div class="timeline-dot" style="background: #084298;"></div>
            <div class="timeline-date">2025-2037</div>
            <div class="timeline-content">
                <h4 class="font-semibold">🎯 FourLight-3 Phase 3 PIVOTAL - First-Line (NCT06760637)</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Pivotal Trial Design</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Open-label, randomized 1:1, global multicenter
                        <br><strong>Population:</strong> 1st-line HR+/HER2- MBC, no prior systemic therapy for advanced disease
                        <br><strong>N=1020:</strong> Event-driven (likely ~600 PFS events)
                        <br><strong>Arms:</strong>
                        <br>• Atirmociclib 300mg BID + letrozole 2.5mg QD
                        <br>• Investigator's choice CDK4/6i (palbo/ribo/abema) + letrozole
                        <br><strong>Investment:</strong> $300-500M+ commitment
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Control Arm Analysis</h5>
                    <p class="detail-text">
                        <strong>Why Acceptable:</strong> Head-to-head vs true 1L SoC (CDK4/6i + AI)
                        <br><strong>Squishiness Problem:</strong> Three different CDK4/6is allowed
                        <br>• Palbociclib: ~25-month median PFS
                        <br>• Ribociclib: ~25-month median PFS
                        <br>• Abemaciclib: ~28-month median PFS
                        <br><strong>Heterogeneity Impact:</strong> Dilutes observed differences
                        <br><strong>Missing Stratification:</strong> Should stratify by chosen CDK4/6i
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Statistical Analysis Plan</h5>
                    <p class="detail-text">
                        <strong>Primary:</strong> PFS by BICR (mitigates open-label bias)
                        <br><strong>Design:</strong> Likely non-inferiority → superiority testing
                        <br><strong>NI Margin:</strong> Not posted (typically HR 1.20-1.30)
                        <br><strong>Power:</strong> 80-90% for NI, ~50% for superiority
                        <br><strong>Alpha Split:</strong> Not specified publicly
                        <br><strong>Hierarchy:</strong> PFS → OS → ORR → PROs
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Interim Analyses & Futility</h5>
                    <p class="detail-text">
                        <strong>Interims:</strong> Not posted but expected at 50% and 75% of events
                        <br><strong>DMC:</strong> Independent committee likely in place
                        <br><strong>Futility Boundary:</strong> Probably HR >1.0 at interim
                        <br><strong>Early Stop for Efficacy:</strong> Unlikely given NI design
                        <br><strong>Crossover:</strong> Policy not stated - critical for OS power
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Sample Size Assumptions</h5>
                    <p class="detail-text">
                        <strong>Control PFS:</strong> ~25 months (weighted average of CDK4/6is)
                        <br><strong>Target HR:</strong> 0.80 for superiority claim
                        <br><strong>Accrual:</strong> 24-30 months
                        <br><strong>Follow-up:</strong> Additional 24+ months for events
                        <br><strong>Total Timeline:</strong> 4-5 years to primary analysis
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">PRO & AE Capture</h5>
                    <p class="detail-text">
                        <strong>AEs:</strong> Investigator-reported CTCAE v5.0
                        <br><strong>PROs:</strong> "QoL" mentioned but instruments not specified
                        <br><strong>Expected:</strong> EORTC QLQ-C30/BR23, EQ-5D-5L
                        <br><strong>BICR:</strong> Central imaging for primary endpoint (key strength)
                        <br><strong>Regional Monitoring:</strong> Critical given global sites including China
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Line of Therapy Implications</h5>
                    <p class="detail-text">
                        <strong>1L Positioning:</strong> Direct competition with established CDK4/6is
                        <br><strong>Differentiation Needed:</strong> Must show better safety (less neutropenia)
                        <br><strong>US Practice:</strong> Would replace palbociclib/ribociclib/abemaciclib
                        <br><strong>Label:</strong> "In combination with AI for 1L HR+/HER2- MBC"
                        <br><strong>Exclusions:</strong> No CNS disease, no early relapse on adjuvant CDK4/6i
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Regional Strategy & China Inclusion</h5>
                    <p class="detail-text">
                        <strong>Global Sites:</strong> US, EU, China, Japan, Korea, Taiwan, LatAm
                        <br><strong>China Risk:</strong> Known AE under-reporting, efficacy inflation
                        <br><strong>Mitigation:</strong> 
                        <br>• BICR reduces imaging bias
                        <br>• Plan per-region safety analysis
                        <br>• Monitor site-level data quality
                        <br><strong>Regulatory:</strong> China inclusion enables NMPA submission
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Go/No-Go Investment Thresholds</h5>
                    <p class="detail-text">
                        <strong>Company Bar:</strong> Non-inferiority likely sufficient
                        <br><strong>Investor Bar:</strong> Need superiority or major safety advantage
                        <br><strong>Budget:</strong> $300-500M through completion
                        <br><strong>Decision Points:</strong>
                        <br>• Interim 1 (50% events): Continue if HR <1.0
                        <br>• Interim 2 (75% events): Continue if trending toward NI
                        <br>• Final: Approve if meets NI, celebrate if superior
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-medium"></div>
                    <div>
                        <strong>Investment Assessment:</strong> Well-designed pivotal with BICR and appropriate control. Heterogeneous comparator and open-label design are weaknesses. Success requires demonstrating meaningful safety advantage to justify switching from established CDK4/6is.
                    </div>
                </div>

                <div class="reference-list">
                    Sources: ClinicalTrials.gov NCT06760637 | Dana-Farber | ASCO | Pfizer Pipeline
                </div>
            </div>
        </div>

        <!-- Regional Bridging Studies -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2023-2024</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Regional Bridging Studies - Critical for Global Filing</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">China PK/Safety Study (NCT05732428)</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Open-label, single-arm in Chinese patients
                        <br><strong>N=9:</strong> Small bridging study for NMPA
                        <br><strong>Dose:</strong> 300mg BID (RP2D from global study)
                        <br><strong>Primary:</strong> PK parameters (Cmax, AUC, T1/2)
                        <br><strong>Key Finding:</strong> Exposure comparable to Western populations
                        <br><strong>Safety:</strong> No new signals but n too small to detect differences
                        <br><strong>AE Risk:</strong> Chinese studies show "bunch of zeros" in AE reporting
                        <br><strong>Mitigation:</strong> Required for NMPA but don't rely on safety data
                    </p>
                </div>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Japan PK Study (NCT05463952)</h5>
                    <p class="detail-text">
                        <strong>Purpose:</strong> PMDA requirement for Japanese approval
                        <br><strong>Design:</strong> Similar to China study
                        <br><strong>Results:</strong> Comparable PK, no new safety signals
                        <br><strong>Cultural Factor:</strong> Japanese patients also under-report AEs
                        <br><strong>Impact:</strong> Enables inclusion in global trials
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">US Re-Run Requirements</h5>
                    <p class="detail-text">
                        <strong>Pfizer Approach:</strong> Did NOT re-run Phase 1 in US after Asia data
                        <br><strong>GSK Precedent:</strong> "GSK has policy... they redo phase one data in US"
                        <br><strong>Risk:</strong> Asia Phase 1 data "notoriously inflated, AEs underreported"
                        <br><strong>Mitigation:</strong> Global Phase 1 included US sites from start
                        <br><strong>Recommendation:</strong> Require US/EU patient subset analysis
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-high"></div>
                    <div>
                        <strong>Critical Due Diligence:</strong> Request region-stratified safety and efficacy data. Chinese/Japanese cohorts likely show lower AE rates and higher response rates. Weight US/EU data more heavily in benefit-risk assessment.
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- Comprehensive Trial Comparison Table -->
    <div class="subsection-title">Complete Trial Portfolio Summary</div>
    <table class="trial-table">
        <thead>
            <tr>
                <th>Trial</th>
                <th>Phase</th>
                <th>N</th>
                <th>Control</th>
                <th>Blinding</th>
                <th>Primary</th>
                <th>Key Issues</th>
                <th>Investment Risk</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>NCT04557449</td>
                <td>1/2a</td>
                <td>~100</td>
                <td>None</td>
                <td>Open</td>
                <td>MTD/RP2D</td>
                <td>No PROs, Asia bias</td>
                <td><span class="text-yellow-600">Medium</span></td>
            </tr>
            <tr>
                <td>TACTIVE-I</td>
                <td>1b/2</td>
                <td>192</td>
                <td>None</td>
                <td>Open</td>
                <td>Safety</td>
                <td>No biomarker validation</td>
                <td><span class="text-red-600">High</span></td>
            </tr>
            <tr>
                <td>TACTIVE-K</td>
                <td>1b/2</td>
                <td>TBD</td>
                <td>None</td>
                <td>Open</td>
                <td>Safety</td>
                <td>Depends on vepdegestrant</td>
                <td><span class="text-yellow-600">Medium</span></td>
            </tr>
            <tr>
                <td>FourLight-1</td>
                <td>2</td>
                <td>333</td>
                <td>Active</td>
                <td>Open</td>
                <td>PFS (INV)</td>
                <td>Downscoped, heterogeneous control</td>
                <td><span class="text-red-600">High</span></td>
            </tr>
            <tr style="background: #f0f7f6;">
                <td><strong>FourLight-3</strong></td>
                <td><strong>3</strong></td>
                <td><strong>1020</strong></td>
                <td><strong>Active</strong></td>
                <td><strong>Open</strong></td>
                <td><strong>PFS (BICR)</strong></td>
                <td><strong>Pivotal - needs safety edge</strong></td>
                <td><span class="text-green-600"><strong>Medium</strong></span></td>
            </tr>
            <tr>
                <td>China Bridge</td>
                <td>1</td>
                <td>9</td>
                <td>None</td>
                <td>Open</td>
                <td>PK</td>
                <td>AE under-reporting</td>
                <td><span class="text-yellow-600">Low</span></td>
            </tr>
        </tbody>
    </table>

    <!-- Investment Committee Summary -->
    <div class="highlight-box mt-6">
        <h4 class="font-semibold mb-3">Investment Committee Clinical Assessment</h4>
        <p class="detail-text">
            <strong>Program Maturity:</strong> Mixed - strong Phase 1/2a signal but strategic uncertainty shown by FourLight-1 downscoping
            <br><br>
            <strong>Key Strengths:</strong>
            <br>• Compelling 1L efficacy (ORR 58.8%, PFS >16 months)
            <br>• Differentiated safety profile (less neutropenia)
            <br>• FourLight-3 well-designed with BICR
            <br><br>
            <strong>Critical Weaknesses:</strong>
            <br>• No placebo-controlled data (all vs active or uncontrolled)
            <br>• Asia site bias not adequately mitigated
            <br>• Limited value proposition vs generic CDK4/6is
            <br>• FourLight-1 downscoping signals internal doubts
            <br><br>
            <strong>Investment Decision Factors:</strong>
            <br>• FourLight-3 interim at 50% events (2027) - key inflection
            <br>• Need HR ≤0.80 or major safety advantage to justify
            <br>• $300-500M capital requirement through approval
            <br>• Competition from 3 established CDK4/6is going generic
        </p>
    </div>
</div>
        </div>

        <!-- Investment Summary Section -->
        <div class="tab-container mt-6">
            <div class="section-title p-6">Investment Committee Summary</div>
            <div class="p-6">
                <div class="highlight-box">
                    <h3 class="text-xl font-bold mb-4 text-gray-900">Executive Investment Thesis</h3>
                    <p class="detail-text">
                        Atirmociclib represents a compelling late-stage oncology investment with validated mechanism, strong Phase 2 proof-of-concept, and clear differentiation through superior safety profile. As the first CDK4-selective inhibitor to reach Phase 3, it addresses the primary limitation of current CDK4/6 inhibitors (neutropenia) while maintaining efficacy through continuous dosing.
                    </p>
                </div>

                <div class="metric-grid mt-6">
                    <div class="metric-card">
                        <div class="metric-label">Clinical Risk</div>
                        <div class="metric-value text-green-600">✓ Low</div>
                        <div class="metric-detail">Strong Phase 2, validated target</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Regulatory Risk</div>
                        <div class="metric-value text-green-600">✓ Low</div>
                        <div class="metric-detail">Precedented pathway, no CDx</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Commercial Risk</div>
                        <div class="metric-value text-yellow-600">⚠ High</div>
                        <div class="metric-detail">Generic competition 2027</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Financial Upside</div>
                        <div class="metric-value text-yellow-600">⚠ Moderate</div>
                        <div class="metric-detail">$2B base case peak sales</div>
                    </div>
                </div>

                <div class="data-card mt-6">
                    <h4 class="font-semibold mb-3">Key Investment Strengths</h4>
                    <ul class="space-y-2">
                        <li>✓ <strong>3-fold reduction in Grade 3/4 neutropenia</strong> (23.5% vs 60-70% palbociclib)</li>
                        <li>✓ <strong>Continuous daily dosing</strong> with 99% dose intensity maintenance</li>
                        <li>✓ <strong>Strong Phase 2 efficacy:</strong> 58.8% ORR, 94.1% CBR in first-line</li>
                        <li>✓ <strong>Comprehensive IP protection</strong> to mid-2040s</li>
                        <li>✓ <strong>Pfizer's execution capabilities</strong> and existing infrastructure</li>
                        <li>✓ <strong>First-mover advantage</strong> in CDK4-selective class</li>
                        <li>✓ <strong>Strategic combinations</strong> with vepdegestrant and CDK2 inhibitor</li>
                    </ul>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-3">Key Investment Risks</h4>
                    <ul class="space-y-2">
                        <li>⚠ <strong>Generic palbociclib competition</strong> at launch (2027)</li>
                        <li>⚠ <strong>Ribociclib/abemaciclib OS advantage</strong> without head-to-head data</li>
                        <li>⚠ <strong>Payer restrictions</strong> likely requiring generic failure first</li>
                        <li>⚠ <strong>Non-inferiority design</strong> may limit differentiation claims</li>
                        <li>⚠ <strong>Emerging CDK4-selective competitors</strong> (BeiGene, Roche)</li>
                        <li>⚠ <strong>FourLight-1 deprioritization</strong> signals limited 2L opportunity</li>
                    </ul>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-3">Financial Return Projections</h4>
                    <table class="trial-table">
                        <thead>
                            <tr>
                                <th>Metric</th>
                                <th>Bull Case</th>
                                <th>Base Case</th>
                                <th>Bear Case</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Peak Sales</td>
                                <td>$5-6B</td>
                                <td>$2B</td>
                                <td>$0.5-1B</td>
                            </tr>
                            <tr>
                                <td>Probability</td>
                                <td>20%</td>
                                <td>60%</td>
                                <td>20%</td>
                            </tr>
                            <tr>
                                <td>NPV @ 10%</td>
                                <td>$8-10B</td>
                                <td>$5B</td>
                                <td>$1-2B</td>
                            </tr>
                            <tr>
                                <td>IRR</td>
                                <td>35-40%</td>
                                <td>25-30%</td>
                                <td>15-20%</td>
                            </tr>
                            <tr style="background: #f0f7f6;">
                                <td><strong>Weighted NPV</strong></td>
                                <td colspan="3" style="text-align: center;"><strong>$5B</strong></td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="highlight-box mt-6">
                    <h4 class="font-semibold mb-2">Investment Recommendation</h4>
                    <p class="detail-text">
                        <strong>Rating: BUY with commercial risk mitigation focus</strong>
                        <br><br>
                        Atirmociclib presents a solid late-stage opportunity with strong scientific rationale and execution capabilities, tempered by significant commercial headwinds from generic competition. The $5B risk-adjusted NPV supports continued investment, but success requires:
                        <br><br>
                        1. <strong>Aggressive payer strategy</strong> emphasizing total cost of care reduction
                        <br>2. <strong>Combination development acceleration</strong> (vepdegestrant combo for differentiation)
                        <br>3. <strong>Real-world evidence generation</strong> demonstrating reduced healthcare utilization
                        <br>4. <strong>Strategic pricing</strong> potentially at parity or below branded competitors
                        <br><br>
                        For external investors (Blackstone), consider royalty financing ($500M-1B for 3-5% royalty) or milestone-based investment tied to commercial uptake metrics. The 25-30% IRR in base case is attractive for late-stage oncology, though commercial risk requires careful structuring.
                        <br><br>
                        <strong>Critical Success Factors:</strong> (1) Phase 3 meets primary endpoint, (2) Safety advantage maintained in larger population, (3) Rapid guideline inclusion, (4) Effective transition from Ibrance franchise, (5) Combination data supporting proprietary regimens.
                    </p>
                </div>

           
            </div>
        </div>
    </div>

    <script>
        // Tab switching function
        function showTab(tabName) {
            document.querySelectorAll('.tab-content').forEach(tab => {
                tab.classList.remove('active');
            });
            
            document.querySelectorAll('.tab-btn').forEach(btn => {
                btn.classList.remove('active');
            });
            
            document.getElementById(tabName).classList.add('active');
            event.target.classList.add('active');
        }

        // Toggle expandable sections
        function toggleSection(header) {
            const content = header.nextElementSibling;
            const arrow = header.querySelector('span:last-child');
            
            if (content.classList.contains('active')) {
                content.classList.remove('active');
                arrow.textContent = '▶';
            } else {
                content.classList.add('active');
                arrow.textContent = '▼';
            }
        }

        // Efficacy Chart
        const efficacyCtx = document.getElementById('efficacyChart');
        if (efficacyCtx) {
            new Chart(efficacyCtx.getContext('2d'), {
                type: 'bar',
                data: {
                    labels: ['ORR', 'CBR', '6-mo PFS Rate', 'Dose Intensity'],
                    datasets: [{
                        label: 'Atirmociclib + Letrozole',
                        data: [58.8, 94.1, 74, 99.3],
                        backgroundColor: '#0a6b5e',
                        borderColor: '#0a6b5e',
                        borderWidth: 1
                    }, {
                        label: 'Historical Palbociclib + Letrozole',
                        data: [42, 85, 65, 70],
                        backgroundColor: '#e3f2f0',
                        borderColor: '#0a6b5e',
                        borderWidth: 1
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: true,
                    plugins: {
                        title: {
                            display: true,
                            text: 'Phase 1/2 Efficacy Outcomes (%)'
                        }
                    },
                    scales: {
                        y: {
                            beginAtZero: true,
                            max: 100,
                            title: {
                                display: true,
                                text: 'Percentage (%)'
                            }
                        }
                    }
                }
            });
        }

        // Market Size Chart
        const marketCtx = document.getElementById('marketChart');
        if (marketCtx) {
            new Chart(marketCtx.getContext('2d'), {
                type: 'pie',
                data: {
                    labels: ['United States', 'Europe', 'China', 'Japan', 'Rest of World'],
                    datasets: [{
                        data: [45, 25, 15, 8, 7],
                        backgroundColor: [
                            '#0a6b5e',
                            '#2c8a7f',
                            '#4ea9a0',
                            '#70c8c1',
                            '#92e7e2'
                        ]
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: true,
                    plugins: {
                        title: {
                            display: true,
                            text: 'CDK4/6 Inhibitor Market by Region (% Revenue)'
                        },
                        legend: {
                            position: 'bottom'
                        }
                    }
                }
            });
        }

        // NPV Scenarios Chart
        const npvCtx = document.getElementById('npvChart');
        if (npvCtx) {
            new Chart(npvCtx.getContext('2d'), {
                type: 'line',
                data: {
                    labels: ['2028', '2029', '2030', '2031', '2032', '2033', '2034', '2035'],
                    datasets: [{
                        label: 'Bull Case',
                        data: [500, 2000, 4000, 5500, 5800, 6000, 5800, 5500],
                        borderColor: '#28a745',
                        backgroundColor: 'rgba(40, 167, 69, 0.1)',
                        tension: 0.4
                    }, {
                        label: 'Base Case',
                        data: [200, 800, 1500, 2000, 2000, 2000, 1900, 1800],
                        borderColor: '#0a6b5e',
                        backgroundColor: 'rgba(10, 107, 94, 0.1)',
                        tension: 0.4
                    }, {
                        label: 'Bear Case',
                        data: [100, 300, 500, 700, 800, 800, 700, 600],
                        borderColor: '#dc3545',
                        backgroundColor: 'rgba(220, 53, 69, 0.1)',
                        tension: 0.4
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: true,
                    plugins: {
                        title: {
                            display: true,
                            text: 'Revenue Projections by Scenario ($M)'
                        }
                    },
                    scales: {
                        y: {
                            beginAtZero: true,
                            title: {
                                display: true,
                                text: 'Revenue ($M)'
                            }
                        }
                    }
                }
            });
        }

        // Safety Comparison Chart
        const safetyCtx = document.getElementById('safetyComparisonChart');
        if (safetyCtx) {
            new Chart(safetyCtx.getContext('2d'), {
                type: 'bar',
                data: {
                    labels: ['Grade 3/4 Neutropenia', 'Dose Reductions', 'Discontinuations', 'Febrile Neutropenia'],
                    datasets: [{
                        label: 'Atirmociclib (%)',
                        data: [23.5, 8.8, 2.9, 0],
                        backgroundColor: '#0a6b5e'
                    }, {
                        label: 'Palbociclib (%)',
                        data: [66, 36, 9.7, 2],
                        backgroundColor: '#e3f2f0'
                    }]
                },
                options: {
                     indexAxis: 'y',
                    responsive: true,
                    maintainAspectRatio: true,
                    plugins: {
                        title: {
                            display: true,
                            text: 'Safety Profile Comparison'
                        }
                    },
                    scales: {
                        x: {
                            beginAtZero: true,
                            max: 70,
                            title: {
                                display: true,
                                text: 'Incidence (%)'
                            }
                        }
                    }
                }
            });
        }
           document.addEventListener('DOMContentLoaded', function() {
            lucide.createIcons();
        });
    </script>
</body>
</html>